AU2007215247B2 - Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors - Google Patents

Info

Publication number

AU2007215247B2

AU2007215247B2 AU2007215247A AU2007215247A AU2007215247B2 AU 2007215247 B2 AU2007215247 B2 AU 2007215247B2 AU 2007215247 A AU2007215247 A AU 2007215247A AU 2007215247 A AU2007215247 A AU 2007215247A AU 2007215247 B2 AU2007215247 B2 AU 2007215247B2

Authority

AU

Australia

Prior art keywords

indazol

carboxylic acid

cancer

amide

mmol

Prior art date

2006-02-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 207
• 239000000203 mixture Substances 0.000 title description 104
• 239000003719 aurora kinase inhibitor Substances 0.000 title description 16
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title description 8
• 150000001875 compounds Chemical class 0.000 claims abstract description 173
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 93
• 102000003989 Aurora kinases Human genes 0.000 claims abstract description 79
• 108090000433 Aurora kinases Proteins 0.000 claims abstract description 79
• 201000011510 cancer Diseases 0.000 claims abstract description 42
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 34
• 238000011282 treatment Methods 0.000 claims abstract description 26
• -1 4-dimethylaminopiperidin-l-yl Chemical group 0.000 claims description 363
• 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 58
• KEJFADGISRFLFO-UHFFFAOYSA-N 1H-indazol-6-amine Chemical compound NC1=CC=C2C=NNC2=C1 KEJFADGISRFLFO-UHFFFAOYSA-N 0.000 claims description 51
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
• 150000003839 salts Chemical class 0.000 claims description 39
• 125000001424 substituent group Chemical group 0.000 claims description 39
• 239000002253 acid Substances 0.000 claims description 38
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
• 230000001404 mediated effect Effects 0.000 claims description 28
• 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 24
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 24
• 229960001433 erlotinib Drugs 0.000 claims description 24
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 24
• 229960005277 gemcitabine Drugs 0.000 claims description 24
• 229960000575 trastuzumab Drugs 0.000 claims description 23
• 239000003795 chemical substances by application Substances 0.000 claims description 20
• 239000003814 drug Substances 0.000 claims description 19
• 150000001408 amides Chemical class 0.000 claims description 16
• 206010006187 Breast cancer Diseases 0.000 claims description 15
• 208000026310 Breast neoplasm Diseases 0.000 claims description 15
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 15
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 14
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 14
• 201000002528 pancreatic cancer Diseases 0.000 claims description 14
• 238000002360 preparation method Methods 0.000 claims description 14
• 206010009944 Colon cancer Diseases 0.000 claims description 13
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 13
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
• 206010060862 Prostate cancer Diseases 0.000 claims description 10
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
• 206010017758 gastric cancer Diseases 0.000 claims description 9
• 201000011549 stomach cancer Diseases 0.000 claims description 9
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
• 125000004551 isoquinolin-3-yl group Chemical group C1=NC(=CC2=CC=CC=C12)* 0.000 claims description 6
• 125000001624 naphthyl group Chemical group 0.000 claims description 6
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 5
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
• 206010005003 Bladder cancer Diseases 0.000 claims description 5
• 206010005949 Bone cancer Diseases 0.000 claims description 5
• 208000018084 Bone neoplasm Diseases 0.000 claims description 5
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
• 206010033128 Ovarian cancer Diseases 0.000 claims description 5
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
• 206010038389 Renal cancer Diseases 0.000 claims description 5
• 206010039491 Sarcoma Diseases 0.000 claims description 5
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 201000010536 head and neck cancer Diseases 0.000 claims description 5
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
• 201000010982 kidney cancer Diseases 0.000 claims description 5
• 208000032839 leukemia Diseases 0.000 claims description 5
• 201000005202 lung cancer Diseases 0.000 claims description 5
• 208000020816 lung neoplasm Diseases 0.000 claims description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 4
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
• 239000002502 liposome Substances 0.000 claims description 3
• AISDZXDUJKGHKF-UHFFFAOYSA-N n-(1h-indazol-6-yl)-6-piperazin-1-yl-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1NC1=NC2=CC(C(=O)NC=3C=C4NN=CC4=CC=3)=C(N3CCNCC3)C=C2N1 AISDZXDUJKGHKF-UHFFFAOYSA-N 0.000 claims description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
• 230000000340 anti-metabolite Effects 0.000 claims description 2
• 229940100197 antimetabolite Drugs 0.000 claims description 2
• 239000002256 antimetabolite Substances 0.000 claims description 2
• 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 claims description 2
• 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 2
• 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 2
• 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
• 206010025323 Lymphomas Diseases 0.000 claims 4
• FUJSJWRORKKPAI-UHFFFAOYSA-N 2-(2,4-dichlorophenoxy)acetyl chloride Chemical compound ClC(=O)COC1=CC=C(Cl)C=C1Cl FUJSJWRORKKPAI-UHFFFAOYSA-N 0.000 claims 2
• ACQKCFILAOYJAH-UHFFFAOYSA-N 6-(diethylamino)-N-(1H-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-3H-benzimidazole-5-carboxamide Chemical compound N=1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(N(CC)CC)=CC=2NC=1NC1=CC=CC=C1C(F)(F)F ACQKCFILAOYJAH-UHFFFAOYSA-N 0.000 claims 1
• 229960002130 benzoin Drugs 0.000 claims 1
• 239000000243 solution Substances 0.000 description 134
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 122
• 239000007787 solid Substances 0.000 description 109
• 230000015572 biosynthetic process Effects 0.000 description 82
• XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 79
• 238000003786 synthesis reaction Methods 0.000 description 72
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
• 239000011541 reaction mixture Substances 0.000 description 69
• 239000000047 product Substances 0.000 description 65
• 125000000217 alkyl group Chemical group 0.000 description 55
• 239000002904 solvent Substances 0.000 description 53
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 52
• 230000002829 reductive effect Effects 0.000 description 51
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 47
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 46
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
• 210000004027 cell Anatomy 0.000 description 44
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 42
• 230000005764 inhibitory process Effects 0.000 description 38
• 238000007363 ring formation reaction Methods 0.000 description 38
• 238000001914 filtration Methods 0.000 description 37
• 238000005984 hydrogenation reaction Methods 0.000 description 37
• 150000004985 diamines Chemical class 0.000 description 36
• 238000003556 assay Methods 0.000 description 35
• 235000019439 ethyl acetate Nutrition 0.000 description 34
• 238000000746 purification Methods 0.000 description 34
• 238000006467 substitution reaction Methods 0.000 description 33
• 125000003118 aryl group Chemical group 0.000 description 31
• 208000035475 disorder Diseases 0.000 description 30
• GAMXVSWLMKRBAC-UHFFFAOYSA-N n-(1h-indazol-6-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1=C2NC=NC2=CC(C(NC=2C=C3NN=CC3=CC=2)=O)=C1 GAMXVSWLMKRBAC-UHFFFAOYSA-N 0.000 description 30
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 29
• 125000000753 cycloalkyl group Chemical group 0.000 description 29
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
• 238000011065 in-situ storage Methods 0.000 description 27
• 150000002828 nitro derivatives Chemical class 0.000 description 27
• 108090000765 processed proteins & peptides Proteins 0.000 description 27
• 238000003756 stirring Methods 0.000 description 27
• 125000000623 heterocyclic group Chemical group 0.000 description 26
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
• 239000003112 inhibitor Substances 0.000 description 25
• UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 25
• 150000002540 isothiocyanates Chemical class 0.000 description 24
• 102000004190 Enzymes Human genes 0.000 description 23
• 108090000790 Enzymes Proteins 0.000 description 23
• 230000000694 effects Effects 0.000 description 21
• 125000001072 heteroaryl group Chemical group 0.000 description 21
• 230000009466 transformation Effects 0.000 description 21
• FCEKLQPJGXIQRY-UHFFFAOYSA-N 1-isothiocyanato-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1N=C=S FCEKLQPJGXIQRY-UHFFFAOYSA-N 0.000 description 20
• 230000004614 tumor growth Effects 0.000 description 20
• 150000001412 amines Chemical class 0.000 description 19
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
• 238000006243 chemical reaction Methods 0.000 description 18
• 238000009472 formulation Methods 0.000 description 18
• 238000010992 reflux Methods 0.000 description 18
• 238000010898 silica gel chromatography Methods 0.000 description 18
• 150000002148 esters Chemical class 0.000 description 17
• 239000003981 vehicle Substances 0.000 description 16
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
• 239000003480 eluent Substances 0.000 description 15
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
• 125000003342 alkenyl group Chemical group 0.000 description 14
• 125000000304 alkynyl group Chemical group 0.000 description 14
• 239000000725 suspension Substances 0.000 description 14
• FAYAYUOZWYJNBD-UHFFFAOYSA-N 1,3-benzothiazol-6-amine Chemical compound NC1=CC=C2N=CSC2=C1 FAYAYUOZWYJNBD-UHFFFAOYSA-N 0.000 description 13
• COYPLDIXZODDDL-UHFFFAOYSA-N 3h-benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CNC2=C1 COYPLDIXZODDDL-UHFFFAOYSA-N 0.000 description 13
• 241000699670 Mus sp. Species 0.000 description 13
• 239000003085 diluting agent Substances 0.000 description 13
• 230000002401 inhibitory effect Effects 0.000 description 13
• VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 13
• 239000003039 volatile agent Substances 0.000 description 13
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 12
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
• 108091000080 Phosphotransferase Proteins 0.000 description 12
• 239000012267 brine Substances 0.000 description 12
• 102000020233 phosphotransferase Human genes 0.000 description 12
• 230000009467 reduction Effects 0.000 description 12
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
• 239000008227 sterile water for injection Substances 0.000 description 12
• 239000000758 substrate Substances 0.000 description 12
• 229940124597 therapeutic agent Drugs 0.000 description 12
• PHAIVWUDAKMNQE-UHFFFAOYSA-N 4-amino-2-chloro-n-(1h-indazol-6-yl)-5-nitrobenzamide Chemical compound C1=C([N+]([O-])=O)C(N)=CC(Cl)=C1C(=O)NC1=CC=C(C=NN2)C2=C1 PHAIVWUDAKMNQE-UHFFFAOYSA-N 0.000 description 11
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
• 229940123877 Aurora kinase inhibitor Drugs 0.000 description 11
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
• 102000001253 Protein Kinase Human genes 0.000 description 11
• 125000004429 atom Chemical group 0.000 description 11
• 125000004432 carbon atom Chemical group C* 0.000 description 11
• 230000004663 cell proliferation Effects 0.000 description 11
• 108060006633 protein kinase Proteins 0.000 description 11
• 230000004044 response Effects 0.000 description 11
• CGDKSBDBNRKQTR-UHFFFAOYSA-N 2-(2-propan-2-ylanilino)-3h-benzimidazole-5-carboxylic acid Chemical compound CC(C)C1=CC=CC=C1NC1=NC2=CC(C(O)=O)=CC=C2N1 CGDKSBDBNRKQTR-UHFFFAOYSA-N 0.000 description 10
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 10
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
• 239000003153 chemical reaction reagent Substances 0.000 description 10
• 201000010099 disease Diseases 0.000 description 10
• 235000019441 ethanol Nutrition 0.000 description 10
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 10
• 239000005441 aurora Substances 0.000 description 9
• 230000036961 partial effect Effects 0.000 description 9
• 230000002062 proliferating effect Effects 0.000 description 9
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 8
• JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 8
• 239000004215 Carbon black (E152) Substances 0.000 description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 8
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
• YBWNBUNOKDDPHY-UHFFFAOYSA-N N-(1,3-benzothiazol-6-yl)-3H-benzimidazole-5-carboxamide Chemical compound C1=C2NC=NC2=CC(C(NC=2C=C3SC=NC3=CC=2)=O)=C1 YBWNBUNOKDDPHY-UHFFFAOYSA-N 0.000 description 8
• 230000012010 growth Effects 0.000 description 8
• 125000001188 haloalkyl group Chemical group 0.000 description 8
• 229930195733 hydrocarbon Natural products 0.000 description 8
• 239000000546 pharmaceutical excipient Substances 0.000 description 8
• 239000003755 preservative agent Substances 0.000 description 8
• 108090000623 proteins and genes Proteins 0.000 description 8
• 102000004169 proteins and genes Human genes 0.000 description 8
• 239000011734 sodium Substances 0.000 description 8
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
• 125000003545 alkoxy group Chemical group 0.000 description 7
• 239000000872 buffer Substances 0.000 description 7
• 238000001514 detection method Methods 0.000 description 7
• 239000000284 extract Substances 0.000 description 7
• 229910052739 hydrogen Inorganic materials 0.000 description 7
• 229910052757 nitrogen Inorganic materials 0.000 description 7
• 239000002244 precipitate Substances 0.000 description 7
• CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 7
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 6
• ZLBJBINCSSCSLN-UHFFFAOYSA-N 2-chloro-4-fluoro-n-(1h-indazol-6-yl)-5-nitrobenzamide Chemical compound C1=C(F)C([N+](=O)[O-])=CC(C(=O)NC=2C=C3NN=CC3=CC=2)=C1Cl ZLBJBINCSSCSLN-UHFFFAOYSA-N 0.000 description 6
• YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 6
• JJABDKZIKAIBGF-UHFFFAOYSA-N 3,4-diamino-n-(1h-indazol-6-yl)benzamide Chemical compound C1=C(N)C(N)=CC=C1C(=O)NC1=CC=C(C=NN2)C2=C1 JJABDKZIKAIBGF-UHFFFAOYSA-N 0.000 description 6
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• 125000002947 alkylene group Chemical group 0.000 description 6
• 125000005215 cycloalkylheteroaryl group Chemical group 0.000 description 6
• 235000014113 dietary fatty acids Nutrition 0.000 description 6
• 239000002552 dosage form Substances 0.000 description 6
• 239000000194 fatty acid Substances 0.000 description 6
• 229930195729 fatty acid Natural products 0.000 description 6
• 150000004665 fatty acids Chemical class 0.000 description 6
• 239000000796 flavoring agent Substances 0.000 description 6
• 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 6
• 239000001257 hydrogen Substances 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 239000000543 intermediate Substances 0.000 description 6
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
• 235000019341 magnesium sulphate Nutrition 0.000 description 6
• 235000010355 mannitol Nutrition 0.000 description 6
• 230000026731 phosphorylation Effects 0.000 description 6
• 238000006366 phosphorylation reaction Methods 0.000 description 6
• 229940002612 prodrug Drugs 0.000 description 6
• 239000000651 prodrug Substances 0.000 description 6
• XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 6
• 239000012453 solvate Substances 0.000 description 6
• 239000003765 sweetening agent Substances 0.000 description 6
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• FSVMVDPUHFVVHX-UHFFFAOYSA-N 2-(2,4-dichloroanilino)-3h-benzimidazole-5-carboxylic acid Chemical compound N=1C2=CC(C(=O)O)=CC=C2NC=1NC1=CC=C(Cl)C=C1Cl FSVMVDPUHFVVHX-UHFFFAOYSA-N 0.000 description 5
• JBVGNBWLFMIRLI-UHFFFAOYSA-N 2-amino-4-fluoro-n-(1h-indazol-6-yl)-5-nitrobenzamide Chemical compound NC1=CC(F)=C([N+]([O-])=O)C=C1C(=O)NC1=CC=C(C=NN2)C2=C1 JBVGNBWLFMIRLI-UHFFFAOYSA-N 0.000 description 5
• POOHGZUGIFBJEG-UHFFFAOYSA-N 4,5-diamino-n-(1h-indazol-6-yl)-2-(4-methylpiperazin-1-yl)benzamide Chemical compound C1CN(C)CCN1C1=CC(N)=C(N)C=C1C(=O)NC1=CC=C(C=NN2)C2=C1 POOHGZUGIFBJEG-UHFFFAOYSA-N 0.000 description 5
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
• 229930195725 Mannitol Natural products 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 229960000583 acetic acid Drugs 0.000 description 5
• 239000000908 ammonium hydroxide Substances 0.000 description 5
• 230000000259 anti-tumor effect Effects 0.000 description 5
• 239000012298 atmosphere Substances 0.000 description 5
• 239000007859 condensation product Substances 0.000 description 5
• 230000008878 coupling Effects 0.000 description 5
• 238000010168 coupling process Methods 0.000 description 5
• 238000005859 coupling reaction Methods 0.000 description 5
• 239000012043 crude product Substances 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 238000001952 enzyme assay Methods 0.000 description 5
• 235000003599 food sweetener Nutrition 0.000 description 5
• 230000014509 gene expression Effects 0.000 description 5
• 239000011521 glass Substances 0.000 description 5
• 229910052736 halogen Inorganic materials 0.000 description 5
• 125000005843 halogen group Chemical group 0.000 description 5
• 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 5
• 125000005842 heteroatom Chemical group 0.000 description 5
• 238000000021 kinase assay Methods 0.000 description 5
• 239000000594 mannitol Substances 0.000 description 5
• IOPLHGOSNCJOOO-UHFFFAOYSA-N methyl 3,4-diaminobenzoate Chemical compound COC(=O)C1=CC=C(N)C(N)=C1 IOPLHGOSNCJOOO-UHFFFAOYSA-N 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 239000003381 stabilizer Substances 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• XBTOSRUBOXQWBO-UHFFFAOYSA-N 1h-indazol-5-amine Chemical compound NC1=CC=C2NN=CC2=C1 XBTOSRUBOXQWBO-UHFFFAOYSA-N 0.000 description 4
• ASKUHKPSYMGTKK-UHFFFAOYSA-N 2-(pyridin-2-ylamino)-3h-benzimidazole-5-carboxylic acid Chemical compound N=1C2=CC(C(=O)O)=CC=C2NC=1NC1=CC=CC=N1 ASKUHKPSYMGTKK-UHFFFAOYSA-N 0.000 description 4
• SYZKAFCPWNFONG-UHFFFAOYSA-N 2-chloro-4-fluoro-5-nitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1Cl SYZKAFCPWNFONG-UHFFFAOYSA-N 0.000 description 4
• 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 4
• YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 4
• RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical compound CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 description 4
• NXFZIWHSAARVQX-UHFFFAOYSA-N 4-chloro-2-fluoro-5-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC(C(Cl)=O)=C(F)C=C1Cl NXFZIWHSAARVQX-UHFFFAOYSA-N 0.000 description 4
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
• HPEZUYZDHDCDEI-UHFFFAOYSA-N N-(1H-indazol-6-yl)-3H-benzimidazole-5-carboxamide trihydrochloride Chemical compound Cl.Cl.Cl.C1=C2N=CNC2=CC(C(NC=2C=C3NN=CC3=CC=2)=O)=C1 HPEZUYZDHDCDEI-UHFFFAOYSA-N 0.000 description 4
• 239000002033 PVDF binder Substances 0.000 description 4
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
• LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 125000004450 alkenylene group Chemical group 0.000 description 4
• 125000005275 alkylenearyl group Chemical group 0.000 description 4
• 125000004419 alkynylene group Chemical group 0.000 description 4
• 239000007900 aqueous suspension Substances 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 239000002585 base Substances 0.000 description 4
• YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 210000000481 breast Anatomy 0.000 description 4
• 229910052799 carbon Inorganic materials 0.000 description 4
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
• 239000000460 chlorine Substances 0.000 description 4
• 239000003086 colorant Substances 0.000 description 4
• 238000002648 combination therapy Methods 0.000 description 4
• 125000004367 cycloalkylaryl group Chemical group 0.000 description 4
• 229910001873 dinitrogen Inorganic materials 0.000 description 4
• 239000002270 dispersing agent Substances 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 239000000706 filtrate Substances 0.000 description 4
• 238000003818 flash chromatography Methods 0.000 description 4
• 235000013355 food flavoring agent Nutrition 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 238000010438 heat treatment Methods 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• 229910052760 oxygen Inorganic materials 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
• 239000000600 sorbitol Substances 0.000 description 4
• 239000000375 suspending agent Substances 0.000 description 4
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
• 229940086542 triethylamine Drugs 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• 239000000080 wetting agent Substances 0.000 description 4
• GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 3
• MDYMNDSWYVNRTO-UHFFFAOYSA-N 1-cyclopentyl-2-isothiocyanatoimidazole Chemical compound S=C=NC1=NC=CN1C1CCCC1 MDYMNDSWYVNRTO-UHFFFAOYSA-N 0.000 description 3
• YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical compound C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 description 3
• DEPDDPLQZYCHOH-UHFFFAOYSA-N 1h-imidazol-2-amine Chemical class NC1=NC=CN1 DEPDDPLQZYCHOH-UHFFFAOYSA-N 0.000 description 3
• KKTUQAYCCLMNOA-UHFFFAOYSA-N 2,3-diaminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1N KKTUQAYCCLMNOA-UHFFFAOYSA-N 0.000 description 3
• 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 3
• CZIDZUYPIHOUFI-UHFFFAOYSA-N 2,6-dinitroindazole Chemical compound C1=C([N+](=O)[O-])C=CC2=CN([N+]([O-])=O)N=C21 CZIDZUYPIHOUFI-UHFFFAOYSA-N 0.000 description 3
• BYKKNHBQDRTFDO-UHFFFAOYSA-N 2-chloro-4-fluoro-n-(1h-indazol-5-yl)-5-nitrobenzamide Chemical compound C1=C(F)C([N+](=O)[O-])=CC(C(=O)NC=2C=C3C=NNC3=CC=2)=C1Cl BYKKNHBQDRTFDO-UHFFFAOYSA-N 0.000 description 3
• BEHDMFLYAJTBMG-UHFFFAOYSA-N 2-isothiocyanato-3-methylpyridine Chemical compound CC1=CC=CN=C1N=C=S BEHDMFLYAJTBMG-UHFFFAOYSA-N 0.000 description 3
• KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical compound NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 description 3
• ORZRMRUXSPNQQL-UHFFFAOYSA-N 6-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=C2C=NNC2=C1 ORZRMRUXSPNQQL-UHFFFAOYSA-N 0.000 description 3
• ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 3
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 3
• 239000005711 Benzoic acid Substances 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• SEAWQCBUNHVJGP-UHFFFAOYSA-N Cl.Cl.Cl.NC1=CC=C2C=NNC2=C1 Chemical compound Cl.Cl.Cl.NC1=CC=C2C=NNC2=C1 SEAWQCBUNHVJGP-UHFFFAOYSA-N 0.000 description 3
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 3
• 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 102000001301 EGF receptor Human genes 0.000 description 3
• 108060006698 EGF receptor Proteins 0.000 description 3
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 208000033501 Refractory anemia with excess blasts Diseases 0.000 description 3
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 125000004350 aryl cycloalkyl group Chemical group 0.000 description 3
• 125000000732 arylene group Chemical group 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• 201000008275 breast carcinoma Diseases 0.000 description 3
• 230000010261 cell growth Effects 0.000 description 3
• 230000003833 cell viability Effects 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 125000002993 cycloalkylene group Chemical group 0.000 description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
• 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 230000005284 excitation Effects 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 150000002367 halogens Chemical class 0.000 description 3
• 125000005549 heteroarylene group Chemical group 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 229940102223 injectable solution Drugs 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 229940057995 liquid paraffin Drugs 0.000 description 3
• 230000001394 metastastic effect Effects 0.000 description 3
• 206010061289 metastatic neoplasm Diseases 0.000 description 3
• 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 3
• ODCXSLUJDXWNTK-UHFFFAOYSA-N n-(5-methyl-1h-indazol-6-yl)-6-piperazin-1-yl-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound CC1=CC=2C=NNC=2C=C1NC(=O)C(C(=CC=1N2)N3CCNCC3)=CC=1N=C2NC1=CC=CC=C1C(F)(F)F ODCXSLUJDXWNTK-UHFFFAOYSA-N 0.000 description 3
• 238000006396 nitration reaction Methods 0.000 description 3
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 125000003729 nucleotide group Chemical group 0.000 description 3
• 239000004006 olive oil Substances 0.000 description 3
• 235000008390 olive oil Nutrition 0.000 description 3
• 239000003960 organic solvent Substances 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 239000003186 pharmaceutical solution Substances 0.000 description 3
• 125000003367 polycyclic group Chemical group 0.000 description 3
• 230000036515 potency Effects 0.000 description 3
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 238000003345 scintillation counting Methods 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 239000000741 silica gel Substances 0.000 description 3
• 229910002027 silica gel Inorganic materials 0.000 description 3
• 229910000104 sodium hydride Inorganic materials 0.000 description 3
• ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 3
• IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 3
• 239000003643 water by type Substances 0.000 description 3
• 230000003442 weekly effect Effects 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
• UJZYHMZRXGNDFB-UHFFFAOYSA-N 1,3-benzothiazol-5-amine Chemical compound NC1=CC=C2SC=NC2=C1 UJZYHMZRXGNDFB-UHFFFAOYSA-N 0.000 description 2
• PCVRYEUFVDIBFI-UHFFFAOYSA-N 1-(1h-indazol-6-yl)ethanone Chemical compound CC(=O)C1=CC=C2C=NNC2=C1 PCVRYEUFVDIBFI-UHFFFAOYSA-N 0.000 description 2
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• XYASEAMWMOXAJY-UHFFFAOYSA-N 1-cyclohexyl-2-isothiocyanatobenzene Chemical compound S=C=NC1=CC=CC=C1C1CCCCC1 XYASEAMWMOXAJY-UHFFFAOYSA-N 0.000 description 2
• KGYVFYCLTXAUCY-UHFFFAOYSA-N 1-cyclopentyl-2-isothiocyanatobenzimidazole Chemical compound S=C=NC1=NC2=CC=CC=C2N1C1CCCC1 KGYVFYCLTXAUCY-UHFFFAOYSA-N 0.000 description 2
• QQOOMDSEMQHMIR-UHFFFAOYSA-N 1-isothiocyanato-2-propan-2-ylbenzene Chemical compound CC(C)C1=CC=CC=C1N=C=S QQOOMDSEMQHMIR-UHFFFAOYSA-N 0.000 description 2
• URPBONOUPMXXRG-UHFFFAOYSA-N 1-isothiocyanatoimidazole Chemical compound N(=C=S)N1C=NC=C1 URPBONOUPMXXRG-UHFFFAOYSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• NUYZVDBIVNOTSC-UHFFFAOYSA-N 1H-indazol-6-ol Chemical compound OC1=CC=C2C=NNC2=C1 NUYZVDBIVNOTSC-UHFFFAOYSA-N 0.000 description 2
• FANSCRRHEDYXIH-UHFFFAOYSA-N 1h-indazole-3,6-diamine Chemical compound NC1=CC=C2C(N)=NNC2=C1 FANSCRRHEDYXIH-UHFFFAOYSA-N 0.000 description 2
• DNCVTVVLMRHJCJ-UHFFFAOYSA-N 1h-indazole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=NNC2=C1 DNCVTVVLMRHJCJ-UHFFFAOYSA-N 0.000 description 2
• CZZZABOKJQXEBO-UHFFFAOYSA-N 2,4-dimethylaniline Chemical compound CC1=CC=C(N)C(C)=C1 CZZZABOKJQXEBO-UHFFFAOYSA-N 0.000 description 2
• LBGBAQLRZJLGFK-UHFFFAOYSA-N 2-(2,6-diethylanilino)-3h-benzimidazole-5-carboxylic acid Chemical compound CCC1=CC=CC(CC)=C1NC1=NC2=CC=C(C(O)=O)C=C2N1 LBGBAQLRZJLGFK-UHFFFAOYSA-N 0.000 description 2
• MFUGNMIQOSCYEN-UHFFFAOYSA-N 2-(2-ethylanilino)-3h-benzimidazole-5-carboxylic acid Chemical compound CCC1=CC=CC=C1NC1=NC2=CC(C(O)=O)=CC=C2N1 MFUGNMIQOSCYEN-UHFFFAOYSA-N 0.000 description 2
• DVBKWQZHRJGHOI-UHFFFAOYSA-N 2-[(3-methylthiophen-2-yl)amino]-3h-benzimidazole-5-carboxylic acid Chemical compound C1=CSC(NC=2NC3=CC(=CC=C3N=2)C(O)=O)=C1C DVBKWQZHRJGHOI-UHFFFAOYSA-N 0.000 description 2
• AIKNUOWQOJYBMO-UHFFFAOYSA-N 2-[2-[5-amino-2-[(1-methylsulfonylindazol-6-yl)carbamoyl]-4-nitrophenyl]ethylamino]ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCNCCC1=CC(N)=C([N+]([O-])=O)C=C1C(=O)NC1=CC=C(C=NN2S(C)(=O)=O)C2=C1 AIKNUOWQOJYBMO-UHFFFAOYSA-N 0.000 description 2
• ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
• YYSJPSFVSGNDPP-UHFFFAOYSA-N 2-anilino-3h-benzimidazole-5-carboxylic acid Chemical compound N=1C2=CC(C(=O)O)=CC=C2NC=1NC1=CC=CC=C1 YYSJPSFVSGNDPP-UHFFFAOYSA-N 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
• 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
• VCFALOPOFICVGI-UHFFFAOYSA-N 2-n-(2-propan-2-ylphenyl)-3h-benzimidazole-2,5-diamine Chemical compound CC(C)C1=CC=CC=C1NC1=NC2=CC(N)=CC=C2N1 VCFALOPOFICVGI-UHFFFAOYSA-N 0.000 description 2
• HCGYMSSYSAKGPK-UHFFFAOYSA-N 2-nitro-1h-indole Chemical compound C1=CC=C2NC([N+](=O)[O-])=CC2=C1 HCGYMSSYSAKGPK-UHFFFAOYSA-N 0.000 description 2
• KDHNBWZTRSFBNX-UHFFFAOYSA-N 3-(2-morpholin-4-ylethoxy)-1h-indazol-6-amine Chemical compound N=1NC2=CC(N)=CC=C2C=1OCCN1CCOCC1 KDHNBWZTRSFBNX-UHFFFAOYSA-N 0.000 description 2
• GBBRCIPPCUJVGC-UHFFFAOYSA-N 3-[[5-(diethylamino)-6-(1h-indazol-6-ylcarbamoyl)-1h-benzimidazol-2-yl]amino]benzoic acid Chemical compound N=1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(N(CC)CC)=CC=2NC=1NC1=CC=CC(C(O)=O)=C1 GBBRCIPPCUJVGC-UHFFFAOYSA-N 0.000 description 2
• BTWUGFRXADMVPL-UHFFFAOYSA-N 3-chloro-2-isothiocyanatopyridine Chemical compound ClC1=CC=CN=C1N=C=S BTWUGFRXADMVPL-UHFFFAOYSA-N 0.000 description 2
• SNLFSJXHGYDERQ-UHFFFAOYSA-N 3-methoxy-1h-indazol-6-amine Chemical compound NC1=CC=C2C(OC)=NNC2=C1 SNLFSJXHGYDERQ-UHFFFAOYSA-N 0.000 description 2
• HWSCSUHNTVVKSR-UHFFFAOYSA-N 3-methyl-2h-indazol-6-amine Chemical compound NC1=CC=C2C(C)=NNC2=C1 HWSCSUHNTVVKSR-UHFFFAOYSA-N 0.000 description 2
• IFLKEBSJTZGCJG-UHFFFAOYSA-N 3-methylthiophene-2-carboxylic acid Chemical compound CC=1C=CSC=1C(O)=O IFLKEBSJTZGCJG-UHFFFAOYSA-N 0.000 description 2
• WKCWIUJYZAOAJE-UHFFFAOYSA-N 4,5-diamino-2-(diethylamino)-n-(1h-indazol-6-yl)benzamide Chemical compound CCN(CC)C1=CC(N)=C(N)C=C1C(=O)NC1=CC=C(C=NN2)C2=C1 WKCWIUJYZAOAJE-UHFFFAOYSA-N 0.000 description 2
• GWRSATNRNFYMDI-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=C(NC=2N=C3N(C4CCCC4)CC(F)(F)C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)NC1CCN(C)CC1 GWRSATNRNFYMDI-UHFFFAOYSA-N 0.000 description 2
• YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 2
• YBXNMIBHHSGZRB-UHFFFAOYSA-N 4-amino-2-chloro-n-(1h-indazol-5-yl)-5-nitrobenzamide Chemical compound C1=C([N+]([O-])=O)C(N)=CC(Cl)=C1C(=O)NC1=CC=C(NN=C2)C2=C1 YBXNMIBHHSGZRB-UHFFFAOYSA-N 0.000 description 2
• ZZNAYFWAXZJITH-UHFFFAOYSA-N 4-amino-3-nitrobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1[N+]([O-])=O ZZNAYFWAXZJITH-UHFFFAOYSA-N 0.000 description 2
• QWGQCKHLQSJBSN-UHFFFAOYSA-N 4-amino-n-(1,3-benzothiazol-6-yl)-2-chloro-5-nitrobenzamide Chemical compound C1=C([N+]([O-])=O)C(N)=CC(Cl)=C1C(=O)NC1=CC=C(N=CS2)C2=C1 QWGQCKHLQSJBSN-UHFFFAOYSA-N 0.000 description 2
• OPXKHVIGHKIOHA-UHFFFAOYSA-N 4-amino-n-(1h-indazol-6-yl)-5-nitro-2-piperazin-1-ylbenzamide Chemical compound C=1C=C2C=NNC2=CC=1NC(=O)C=1C=C([N+]([O-])=O)C(N)=CC=1N1CCNCC1 OPXKHVIGHKIOHA-UHFFFAOYSA-N 0.000 description 2
• CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
• ZYKXXTRGRCOWJO-UHFFFAOYSA-N 4-ethynyl-2-nitroaniline Chemical compound NC1=CC=C(C#C)C=C1[N+]([O-])=O ZYKXXTRGRCOWJO-UHFFFAOYSA-N 0.000 description 2
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
• 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
• VZVZWGALLRTOJR-UHFFFAOYSA-N 6-(diethylamino)-n-(1h-indazol-6-yl)-2-[(3-methylpyridin-2-yl)amino]-3h-benzimidazole-5-carboxamide Chemical compound N=1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(N(CC)CC)=CC=2NC=1NC1=NC=CC=C1C VZVZWGALLRTOJR-UHFFFAOYSA-N 0.000 description 2
• KVFCDZKCMXNTQA-UHFFFAOYSA-N 6-(propylamino)-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxylic acid Chemical compound N1C=2C=C(C(O)=O)C(NCCC)=CC=2N=C1NC1=CC=CC=C1C(F)(F)F KVFCDZKCMXNTQA-UHFFFAOYSA-N 0.000 description 2
• JFBOVOSWKVKJAX-UHFFFAOYSA-N 6-[2-(1h-indazol-6-yl)ethyl]-n-[2-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound FC(F)(F)C1=CC=CC=C1NC1=NC2=CC(CCC=3C=C4NN=CC4=CC=3)=CC=C2N1 JFBOVOSWKVKJAX-UHFFFAOYSA-N 0.000 description 2
• AOWNUEXIZUBBBM-UHFFFAOYSA-N 6-[2-(dimethylamino)ethylsulfanyl]-n-(1h-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound N=1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(SCCN(C)C)=CC=2NC=1NC1=CC=CC=C1C(F)(F)F AOWNUEXIZUBBBM-UHFFFAOYSA-N 0.000 description 2
• AZYKAQIJICDKJX-UHFFFAOYSA-N 6-[bis(2-methylpropyl)amino]-n-(1h-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound N1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(N(CC(C)C)CC(C)C)=CC=2N=C1NC1=CC=CC=C1C(F)(F)F AZYKAQIJICDKJX-UHFFFAOYSA-N 0.000 description 2
• DSOPOVSYHDJPMR-UHFFFAOYSA-N 6-chloro-n-(1h-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-1h-benzimidazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1NC1=NC2=CC(C(=O)NC=3C=C4NN=CC4=CC=3)=C(Cl)C=C2N1 DSOPOVSYHDJPMR-UHFFFAOYSA-N 0.000 description 2
• UYPSMSUYMARCRX-UHFFFAOYSA-N 6-nitro-2h-indazole-3-carbaldehyde Chemical compound C1=C([N+](=O)[O-])C=CC2=C(C=O)NN=C21 UYPSMSUYMARCRX-UHFFFAOYSA-N 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• 244000215068 Acacia senegal Species 0.000 description 2
• 235000006491 Acacia senegal Nutrition 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 235000003911 Arachis Nutrition 0.000 description 2
• 244000105624 Arachis hypogaea Species 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• XFIRENMEEJWGPG-UHFFFAOYSA-N Br.C1CN(C)CCN1C(C(=C1)C(=O)NC=2C=C3NN=CC3=CC=2)=CC2=C1N=C(N)N2 Chemical compound Br.C1CN(C)CCN1C(C(=C1)C(=O)NC=2C=C3NN=CC3=CC=2)=CC2=C1N=C(N)N2 XFIRENMEEJWGPG-UHFFFAOYSA-N 0.000 description 2
• 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 2
• 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 2
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 229920000084 Gum arabic Polymers 0.000 description 2
• 229910004373 HOAc Inorganic materials 0.000 description 2
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
• 102100033636 Histone H3.2 Human genes 0.000 description 2
• 108010033040 Histones Proteins 0.000 description 2
• 208000017604 Hodgkin disease Diseases 0.000 description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
• 102000038455 IGF Type 1 Receptor Human genes 0.000 description 2
• 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 239000007993 MOPS buffer Substances 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• 150000001204 N-oxides Chemical class 0.000 description 2
• 229910017974 NH40H Inorganic materials 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
• 206010038270 Refractory anaemia with an excess of blasts Diseases 0.000 description 2
• 208000032411 Refractory with Excess of Blasts Anemia Diseases 0.000 description 2
• 238000011579 SCID mouse model Methods 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical class O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
• 235000010489 acacia gum Nutrition 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 238000010640 amide synthesis reaction Methods 0.000 description 2
• 235000019270 ammonium chloride Nutrition 0.000 description 2
• 239000003098 androgen Substances 0.000 description 2
• 208000036878 aneuploidy Diseases 0.000 description 2
• 231100001075 aneuploidy Toxicity 0.000 description 2
• 230000006023 anti-tumor response Effects 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 239000003637 basic solution Substances 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
• 229910000019 calcium carbonate Inorganic materials 0.000 description 2
• 235000010216 calcium carbonate Nutrition 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000032823 cell division Effects 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• 229940125773 compound 10 Drugs 0.000 description 2
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 125000000392 cycloalkenyl group Chemical group 0.000 description 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 239000002254 cytotoxic agent Substances 0.000 description 2
• 231100000599 cytotoxic agent Toxicity 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 239000000890 drug combination Substances 0.000 description 2
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
• 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 230000008014 freezing Effects 0.000 description 2
• 238000007710 freezing Methods 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 201000005787 hematologic cancer Diseases 0.000 description 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
• 150000002431 hydrogen Chemical class 0.000 description 2
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
• 229940043355 kinase inhibitor Drugs 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
• LONZCIHRNJRCSN-UHFFFAOYSA-N n-(1,3-benzothiazol-6-yl)-2-[(3-methylpyridin-2-yl)amino]-6-piperazin-1-yl-3h-benzimidazole-5-carboxamide Chemical compound CC1=CC=CN=C1NC1=NC2=CC(C(=O)NC=3C=C4SC=NC4=CC=3)=C(N3CCNCC3)C=C2N1 LONZCIHRNJRCSN-UHFFFAOYSA-N 0.000 description 2
• ZMCIIGMZGZYPBW-UHFFFAOYSA-N n-(1h-indazol-5-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1=C2N=CNC2=CC(C(NC=2C=C3C=NNC3=CC=2)=O)=C1 ZMCIIGMZGZYPBW-UHFFFAOYSA-N 0.000 description 2
• JLLUJHNJKJBMQU-UHFFFAOYSA-N n-(1h-indazol-5-yl)-6-(4-methylpiperazin-1-yl)-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound C1CN(C)CCN1C(C(=C1)C(=O)NC=2C=C3C=NNC3=CC=2)=CC2=C1N=C(NC=1C(=CC=CC=1)C(F)(F)F)N2 JLLUJHNJKJBMQU-UHFFFAOYSA-N 0.000 description 2
• ZEPNRHQXDGGJJG-UHFFFAOYSA-N n-(1h-indazol-6-yl)-2-[(3-methylpyridin-2-yl)amino]-6-piperazin-1-yl-3h-benzimidazole-5-carboxamide Chemical compound CC1=CC=CN=C1NC1=NC2=CC(C(=O)NC=3C=C4NN=CC4=CC=3)=C(N3CCNCC3)C=C2N1 ZEPNRHQXDGGJJG-UHFFFAOYSA-N 0.000 description 2
• DAIVJTMGVXDEKA-UHFFFAOYSA-N n-(1h-indazol-6-yl)-6-piperazin-1-yl-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide;trihydrochloride Chemical compound Cl.Cl.Cl.FC(F)(F)C1=CC=CC=C1NC1=NC2=CC(C(=O)NC=3C=C4NN=CC4=CC=3)=C(N3CCNCC3)C=C2N1 DAIVJTMGVXDEKA-UHFFFAOYSA-N 0.000 description 2
• YBPVCKVSPKSPPN-UHFFFAOYSA-N n-(6-amino-1h-indazol-3-yl)-1-methylpiperidine-4-carboxamide Chemical compound C1CN(C)CCC1C(=O)NC1=NNC2=CC(N)=CC=C12 YBPVCKVSPKSPPN-UHFFFAOYSA-N 0.000 description 2
• WYYOKVCAINJIDA-UHFFFAOYSA-N n-[3-(2-morpholin-4-ylethoxy)-1h-indazol-6-yl]-2-(2-propan-2-ylanilino)-3h-benzimidazole-5-carboxamide Chemical compound CC(C)C1=CC=CC=C1NC1=NC2=CC=C(C(=O)NC=3C=C4NN=C(OCCN5CCOCC5)C4=CC=3)C=C2N1 WYYOKVCAINJIDA-UHFFFAOYSA-N 0.000 description 2
• GFZJUQJGJDURHV-UHFFFAOYSA-N n-[3-[(1-methylpiperidine-4-carbonyl)amino]-1h-indazol-6-yl]-2-(2-propan-2-ylanilino)-3h-benzimidazole-5-carboxamide Chemical compound CC(C)C1=CC=CC=C1NC1=NC2=CC=C(C(=O)NC=3C=C4NN=C(NC(=O)C5CCN(C)CC5)C4=CC=3)C=C2N1 GFZJUQJGJDURHV-UHFFFAOYSA-N 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
• 239000002504 physiological saline solution Substances 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
• 235000013772 propylene glycol Nutrition 0.000 description 2
• 229960004063 propylene glycol Drugs 0.000 description 2
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
• 229910052702 rhenium Inorganic materials 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
• JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
• LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
• 235000011069 sorbitan monooleate Nutrition 0.000 description 2
• 239000001593 sorbitan monooleate Substances 0.000 description 2
• 229940035049 sorbitan monooleate Drugs 0.000 description 2
• 230000001954 sterilising effect Effects 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 150000005846 sugar alcohols Polymers 0.000 description 2
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000011593 sulfur Chemical group 0.000 description 2
• XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 2
• 235000010269 sulphur dioxide Nutrition 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• FRMIZSYUBBUOKF-UHFFFAOYSA-N tert-butyl 4-[4,5-diamino-2-(1h-indazol-6-ylcarbamoyl)phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC(N)=C(N)C=C1C(=O)NC1=CC=C(C=NN2)C2=C1 FRMIZSYUBBUOKF-UHFFFAOYSA-N 0.000 description 2
• NSXULXNWTSLXBQ-UHFFFAOYSA-N tert-butyl n-[1-[4,5-diamino-2-(1h-indazol-6-ylcarbamoyl)phenyl]piperidin-4-yl]carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1C1=CC(N)=C(N)C=C1C(=O)NC1=CC=C(C=NN2)C2=C1 NSXULXNWTSLXBQ-UHFFFAOYSA-N 0.000 description 2
• JJJGZRSDYWDTKB-UHFFFAOYSA-N tert-butyl n-[1-[6-(1h-indazol-6-ylcarbamoyl)-2-[(3-methylpyridin-2-yl)amino]-1h-benzimidazol-5-yl]piperidin-4-yl]carbamate Chemical compound CC1=CC=CN=C1NC1=NC2=CC(C(=O)NC=3C=C4NN=CC4=CC=3)=C(N3CCC(CC3)NC(=O)OC(C)(C)C)C=C2N1 JJJGZRSDYWDTKB-UHFFFAOYSA-N 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 239000011123 type I (borosilicate glass) Substances 0.000 description 2
• 239000002691 unilamellar liposome Substances 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• RBGDFYZLQKZUCO-CSMHCCOUSA-N (1r,3s,4s)-3-isothiocyanatobicyclo[2.2.1]heptane Chemical compound C1C[C@@H]2[C@@H](N=C=S)C[C@H]1C2 RBGDFYZLQKZUCO-CSMHCCOUSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
• RBGDFYZLQKZUCO-WTIBDHCWSA-N (4s)-3-isothiocyanatobicyclo[2.2.1]heptane Chemical compound C1CC2CC(N=C=S)[C@]1([H])C2 RBGDFYZLQKZUCO-WTIBDHCWSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
• ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
• WCNVOWWRJIZZKA-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,4-benzodiazepin-5-one Chemical compound O=C1NCCNC2=CC=CC=C12 WCNVOWWRJIZZKA-UHFFFAOYSA-N 0.000 description 1
• GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
• QDPPZHPTDMQNBE-UHFFFAOYSA-N 1,3-diethyl-2-isothiocyanatobenzene Chemical compound CCC1=CC=CC(CC)=C1N=C=S QDPPZHPTDMQNBE-UHFFFAOYSA-N 0.000 description 1
• VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
• FTQOIXBLZHRTFH-UHFFFAOYSA-N 1,3-dioxane-2,4-diyl Chemical group C1C[O+]=CO[CH-]1 FTQOIXBLZHRTFH-UHFFFAOYSA-N 0.000 description 1
• APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
• RCFUXEJPMJFAJE-UHFFFAOYSA-N 1-(pyridin-2-ylamino)benzimidazole-5-carboxylic acid Chemical compound C1=NC2=CC(C(=O)O)=CC=C2N1NC1=CC=CC=N1 RCFUXEJPMJFAJE-UHFFFAOYSA-N 0.000 description 1
• HTUOAGYEGYOIII-UHFFFAOYSA-N 1-(thietan-3-yl)imidazol-2-amine Chemical compound NC1=NC=CN1C1CSC1 HTUOAGYEGYOIII-UHFFFAOYSA-N 0.000 description 1
• WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
• NJKSHSRYEUUIFB-UHFFFAOYSA-N 1-benzyl-2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1CC1=CC=CC=C1 NJKSHSRYEUUIFB-UHFFFAOYSA-N 0.000 description 1
• NYYVBVQVGYJWIN-UHFFFAOYSA-N 1-benzylimidazol-2-amine Chemical compound NC1=NC=CN1CC1=CC=CC=C1 NYYVBVQVGYJWIN-UHFFFAOYSA-N 0.000 description 1
• BXMDAGGQRIDSPA-UHFFFAOYSA-N 1-bromo-2-cyclohexylbenzene Chemical compound BrC1=CC=CC=C1C1CCCCC1 BXMDAGGQRIDSPA-UHFFFAOYSA-N 0.000 description 1
• LXBSSHPWNMYEEA-UHFFFAOYSA-N 1-cyclopentyl-2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1C1CCCC1 LXBSSHPWNMYEEA-UHFFFAOYSA-N 0.000 description 1
• UTVDWVRXWFQCQJ-UHFFFAOYSA-N 1-cyclopentylbenzimidazol-2-amine Chemical compound NC1=NC2=CC=CC=C2N1C1CCCC1 UTVDWVRXWFQCQJ-UHFFFAOYSA-N 0.000 description 1
• KPOCEELKHBZAEK-UHFFFAOYSA-N 1-cyclopentylimidazol-2-amine Chemical compound NC1=NC=CN1C1CCCC1 KPOCEELKHBZAEK-UHFFFAOYSA-N 0.000 description 1
• OVAFDUCMHLFDIG-UHFFFAOYSA-N 1-ethyl-2-isothiocyanatobenzene Chemical compound CCC1=CC=CC=C1N=C=S OVAFDUCMHLFDIG-UHFFFAOYSA-N 0.000 description 1
• PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
• ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical class COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• YTKNUPJYGSOVLV-UHFFFAOYSA-N 1-methylindazol-6-amine Chemical compound C1=C(N)C=C2N(C)N=CC2=C1 YTKNUPJYGSOVLV-UHFFFAOYSA-N 0.000 description 1
• MIVZCINZDWIBJS-UHFFFAOYSA-N 1-methylpiperidine-4-carbonyl chloride Chemical compound CN1CCC(C(Cl)=O)CC1 MIVZCINZDWIBJS-UHFFFAOYSA-N 0.000 description 1
• AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• GDLAPQLBKLYDGT-UHFFFAOYSA-N 1-propan-2-ylimidazol-2-amine Chemical compound CC(C)N1C=CN=C1N GDLAPQLBKLYDGT-UHFFFAOYSA-N 0.000 description 1
• WHKWMTXTYKVFLK-UHFFFAOYSA-N 1-propan-2-ylpiperazine Chemical compound CC(C)N1CCNCC1 WHKWMTXTYKVFLK-UHFFFAOYSA-N 0.000 description 1
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
• DGHHQBMTXTWTJV-BQAIUKQQSA-N 119413-54-6 Chemical compound Cl.C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 DGHHQBMTXTWTJV-BQAIUKQQSA-N 0.000 description 1
• XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• FXHHIBHSTIBQBD-UHFFFAOYSA-N 1h-indazole-3,4-diamine Chemical compound C1=CC(N)=C2C(N)=NNC2=C1 FXHHIBHSTIBQBD-UHFFFAOYSA-N 0.000 description 1
• MIMYTSWNVBMNRH-UHFFFAOYSA-N 1h-indol-6-amine Chemical compound NC1=CC=C2C=CNC2=C1 MIMYTSWNVBMNRH-UHFFFAOYSA-N 0.000 description 1
• YMRIDJQAEZFTSC-UHFFFAOYSA-N 2,3-dihydro-1h-tetrazole Chemical compound N1NC=NN1 YMRIDJQAEZFTSC-UHFFFAOYSA-N 0.000 description 1
• WVBNZZHGECFCSH-UHFFFAOYSA-N 2,4-dichloro-1-isothiocyanatobenzene Chemical compound ClC1=CC=C(N=C=S)C(Cl)=C1 WVBNZZHGECFCSH-UHFFFAOYSA-N 0.000 description 1
• DUIOVGPUAJSYCD-UHFFFAOYSA-N 2,4-dimethyl-5-nitroaniline Chemical compound CC1=CC(C)=C([N+]([O-])=O)C=C1N DUIOVGPUAJSYCD-UHFFFAOYSA-N 0.000 description 1
• IFNWESYYDINUHV-UHFFFAOYSA-N 2,6-dimethylpiperazine Chemical compound CC1CNCC(C)N1 IFNWESYYDINUHV-UHFFFAOYSA-N 0.000 description 1
• KRWYAHLFMDAUFR-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-ylamino)-n-(1h-indazol-6-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1=CC=C2SC(NC=3NC4=CC=C(C=C4N=3)C(NC=3C=C4NN=CC4=CC=3)=O)=NC2=C1 KRWYAHLFMDAUFR-UHFFFAOYSA-N 0.000 description 1
• XBFQQTMNXGEBCV-UHFFFAOYSA-N 2-(2,4-dichloroanilino)-N-(1H-indazol-6-yl)-3H-benzimidazole-5-carboxamide Chemical compound Clc1ccc(Nc2nc3cc(ccc3[nH]2)C(=O)Nc2ccc3cn[nH]c3c2)c(Cl)c1 XBFQQTMNXGEBCV-UHFFFAOYSA-N 0.000 description 1
• JBKBEGQKCKUPSX-UHFFFAOYSA-N 2-(2,4-dichloroanilino)-n-(3-methyl-2h-indazol-6-yl)-3h-benzimidazole-5-carboxamide Chemical compound C=1C=C2C(C)=NNC2=CC=1NC(=O)C(C=C1N2)=CC=C1N=C2NC1=CC=C(Cl)C=C1Cl JBKBEGQKCKUPSX-UHFFFAOYSA-N 0.000 description 1
• VKNHKCYEUIZCTM-UHFFFAOYSA-N 2-(2,4-dichloroanilino)-n-[3-(morpholin-4-ylmethyl)-2h-indazol-6-yl]-3h-benzimidazole-5-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1NC1=NC2=CC=C(C(=O)NC=3C=C4NN=C(CN5CCOCC5)C4=CC=3)C=C2N1 VKNHKCYEUIZCTM-UHFFFAOYSA-N 0.000 description 1
• BFDLIEIKVIXGJC-UHFFFAOYSA-N 2-(2,6-diethylanilino)-n-(1h-indazol-6-yl)-3h-benzimidazole-5-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC1=NC2=CC=C(C(=O)NC=3C=C4NN=CC4=CC=3)C=C2N1 BFDLIEIKVIXGJC-UHFFFAOYSA-N 0.000 description 1
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
• IEBYLYQAHQRWFZ-UHFFFAOYSA-N 2-(2-chloroanilino)-N-(1H-indazol-6-yl)-3H-benzimidazole-5-carboxamide Chemical compound Clc1ccccc1Nc1nc2cc(ccc2[nH]1)C(=O)Nc1ccc2cn[nH]c2c1 IEBYLYQAHQRWFZ-UHFFFAOYSA-N 0.000 description 1
• XIAWYLNYLVWMDL-UHFFFAOYSA-N 2-(2-cyclohexylanilino)-n-(1h-indazol-6-yl)-3h-benzimidazole-5-carboxamide Chemical compound C=1C=C2C=NNC2=CC=1NC(=O)C(C=C1N2)=CC=C1N=C2NC1=CC=CC=C1C1CCCCC1 XIAWYLNYLVWMDL-UHFFFAOYSA-N 0.000 description 1
• UNPOONPXJVOJSE-UHFFFAOYSA-N 2-(2-methoxyanilino)-3h-benzimidazole-5-carboxylic acid Chemical compound COC1=CC=CC=C1NC1=NC2=CC=C(C(O)=O)C=C2N1 UNPOONPXJVOJSE-UHFFFAOYSA-N 0.000 description 1
• OUAGJGIFBVGMSU-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)benzamide Chemical compound C1CN(C)CCN1C1=CC=CC=C1C(N)=O OUAGJGIFBVGMSU-UHFFFAOYSA-N 0.000 description 1
• DKIVBAYGSPWLJA-UHFFFAOYSA-N 2-(5-aminoindazol-1-yl)ethanol Chemical compound NC1=CC=C2N(CCO)N=CC2=C1 DKIVBAYGSPWLJA-UHFFFAOYSA-N 0.000 description 1
• ARJLAPREGBZGMU-UHFFFAOYSA-N 2-(5-nitroindazol-1-yl)ethanol Chemical compound [O-][N+](=O)C1=CC=C2N(CCO)N=CC2=C1 ARJLAPREGBZGMU-UHFFFAOYSA-N 0.000 description 1
• XRWMHJJHPQTTLQ-UHFFFAOYSA-N 2-(chloromethyl)thiirane Chemical compound ClCC1CS1 XRWMHJJHPQTTLQ-UHFFFAOYSA-N 0.000 description 1
• VAVIGMGSOUHIIW-UHFFFAOYSA-N 2-(cyclohexylamino)-6-(diethylamino)-N-(1H-indazol-6-yl)-3H-benzimidazole-5-carboxamide Chemical compound CCN(CC)c1cc2[nH]c(NC3CCCCC3)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 VAVIGMGSOUHIIW-UHFFFAOYSA-N 0.000 description 1
• LAYVAINEAAZFDE-UHFFFAOYSA-N 2-(cyclopentylamino)-6-(diethylamino)-N-(1H-indazol-6-yl)-3H-benzimidazole-5-carboxamide Chemical compound CCN(CC)c1cc2[nH]c(NC3CCCC3)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 LAYVAINEAAZFDE-UHFFFAOYSA-N 0.000 description 1
• ILUMOCLFYZEOAZ-UHFFFAOYSA-N 2-(diethylamino)benzamide Chemical compound CCN(CC)C1=CC=CC=C1C(N)=O ILUMOCLFYZEOAZ-UHFFFAOYSA-N 0.000 description 1
• DENMGZODXQRYAR-UHFFFAOYSA-N 2-(dimethylamino)ethanethiol Chemical compound CN(C)CCS DENMGZODXQRYAR-UHFFFAOYSA-N 0.000 description 1
• MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
• VANXWQNFWFNOCI-UHFFFAOYSA-N 2-(isoquinolin-3-ylamino)-3h-benzimidazole-5-carboxylic acid Chemical compound C1=CC=C2C=NC(NC=3NC4=CC=C(C=C4N=3)C(=O)O)=CC2=C1 VANXWQNFWFNOCI-UHFFFAOYSA-N 0.000 description 1
• KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
• VBLXCTYLWZJBKA-UHFFFAOYSA-N 2-(trifluoromethyl)aniline Chemical compound NC1=CC=CC=C1C(F)(F)F VBLXCTYLWZJBKA-UHFFFAOYSA-N 0.000 description 1
• YKOLZVXSPGIIBJ-UHFFFAOYSA-N 2-Isopropylaniline Chemical compound CC(C)C1=CC=CC=C1N YKOLZVXSPGIIBJ-UHFFFAOYSA-N 0.000 description 1
• DUMGPIQFNUCJNE-UHFFFAOYSA-N 2-[(1-benzylimidazol-2-yl)amino]-n-(1h-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1CN(C)CCN1C(C(=C1)C(=O)NC=2C=C3NN=CC3=CC=2)=CC2=C1N=C(NC=1N(C=CN=1)CC=1C=CC=CC=1)N2 DUMGPIQFNUCJNE-UHFFFAOYSA-N 0.000 description 1
• BXZSXDXUMVDWGM-UHFFFAOYSA-N 2-[(1-cyclopentylbenzimidazol-2-yl)amino]-n-(1h-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1CN(C)CCN1C(C(=C1)C(=O)NC=2C=C3NN=CC3=CC=2)=CC2=C1N=C(NC=1N(C3=CC=CC=C3N=1)C1CCCC1)N2 BXZSXDXUMVDWGM-UHFFFAOYSA-N 0.000 description 1
• XNBMZVUUWHZORT-UHFFFAOYSA-N 2-[(1-cyclopentylimidazol-2-yl)amino]-n-(1h-indazol-5-yl)-6-(4-methylpiperazin-1-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1CN(C)CCN1C(C(=C1)C(=O)NC=2C=C3C=NNC3=CC=2)=CC2=C1N=C(NC=1N(C=CN=1)C1CCCC1)N2 XNBMZVUUWHZORT-UHFFFAOYSA-N 0.000 description 1
• MHMXIVBSMSQWOH-UHFFFAOYSA-N 2-[(1-cyclopentylimidazol-2-yl)amino]-n-(1h-indazol-6-yl)-6-(4-propan-2-ylpiperazin-1-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1CN(C(C)C)CCN1C(C(=C1)C(=O)NC=2C=C3NN=CC3=CC=2)=CC2=C1N=C(NC=1N(C=CN=1)C1CCCC1)N2 MHMXIVBSMSQWOH-UHFFFAOYSA-N 0.000 description 1
• FWXDOFFJAJEPOE-UHFFFAOYSA-N 2-[(1-cyclopentylimidazol-2-yl)amino]-n-(1h-indazol-6-yl)-6-piperazin-1-yl-3h-benzimidazole-5-carboxamide Chemical compound C=1C=C2C=NNC2=CC=1NC(=O)C(C(=CC=1N2)N3CCNCC3)=CC=1N=C2NC1=NC=CN1C1CCCC1 FWXDOFFJAJEPOE-UHFFFAOYSA-N 0.000 description 1
• KZTNSWBEXABMCP-UHFFFAOYSA-N 2-[(1-propan-2-ylimidazol-2-yl)amino]-3h-benzimidazole-5-carboxylic acid Chemical compound CC(C)N1C=CN=C1NC1=NC2=CC=C(C(O)=O)C=C2N1 KZTNSWBEXABMCP-UHFFFAOYSA-N 0.000 description 1
• APVTWCONRGKOEA-UHFFFAOYSA-N 2-[(4,5-dimethyl-1,3-thiazol-2-yl)amino]-N-(1H-indazol-6-yl)-3H-benzimidazole-5-carboxamide Chemical compound Cc1nc(Nc2nc3cc(ccc3[nH]2)C(=O)Nc2ccc3cn[nH]c3c2)sc1C APVTWCONRGKOEA-UHFFFAOYSA-N 0.000 description 1
• YGEWPSQGDYELQR-UHFFFAOYSA-N 2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxylic acid Chemical compound N=1C2=CC(C(=O)O)=CC=C2NC=1NC1=CC=CC=C1C(F)(F)F YGEWPSQGDYELQR-UHFFFAOYSA-N 0.000 description 1
• JFMLKTNDEGGPGC-UHFFFAOYSA-N 2-[4-[6-(1h-indazol-6-ylcarbamoyl)-2-[2-(trifluoromethyl)anilino]-1h-benzimidazol-5-yl]piperazin-1-yl]acetic acid Chemical compound C1CN(CC(=O)O)CCN1C(C(=C1)C(=O)NC=2C=C3NN=CC3=CC=2)=CC2=C1N=C(NC=1C(=CC=CC=1)C(F)(F)F)N2 JFMLKTNDEGGPGC-UHFFFAOYSA-N 0.000 description 1
• LRENGJXPNVZECX-NMOVXWOSSA-N 2-[[(1S,2S,4R)-2-bicyclo[2.2.1]heptanyl]amino]-N-(1H-indazol-6-yl)-6-piperazin-1-yl-3H-benzimidazole-5-carboxamide trihydrochloride Chemical compound Cl.Cl.Cl.N([C@@H]1[C@@]2([H])CC[C@](C2)(C1)[H])C(NC1=C2)=NC1=CC(C(=O)NC=1C=C3NN=CC3=CC=1)=C2N1CCNCC1 LRENGJXPNVZECX-NMOVXWOSSA-N 0.000 description 1
• JZQOEFDFZBAYKO-PEBVRCNWSA-N 2-[[(1r,3s,4s)-3-bicyclo[2.2.1]heptanyl]amino]-6-chloro-n-(1h-indazol-6-yl)-1h-benzimidazole-5-carboxamide Chemical compound C1=C2C=NNC2=CC(NC(=O)C=2C=C3N=C(NC3=CC=2Cl)N[C@@H]2[C@@]3([H])CC[C@](C3)(C2)[H])=C1 JZQOEFDFZBAYKO-PEBVRCNWSA-N 0.000 description 1
• FTTCKOPNZJTMOE-GUXCAODWSA-N 2-[[(1r,3s,4s)-3-bicyclo[2.2.1]heptanyl]amino]-n-(1h-indazol-6-yl)-6-piperazin-1-yl-3h-benzimidazole-5-carboxamide Chemical compound N([C@@H]1[C@@]2([H])CC[C@](C2)(C1)[H])C(NC1=C2)=NC1=CC(C(=O)NC=1C=C3NN=CC3=CC=1)=C2N1CCNCC1 FTTCKOPNZJTMOE-GUXCAODWSA-N 0.000 description 1
• CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 1
• WXZMJSXKWNZCDI-UHFFFAOYSA-N 2-anilino-N-(2H-benzotriazol-5-yl)-3H-benzimidazole-5-carboxamide Chemical compound O=C(Nc1ccc2[nH]nnc2c1)c1ccc2[nH]c(Nc3ccccc3)nc2c1 WXZMJSXKWNZCDI-UHFFFAOYSA-N 0.000 description 1
• LAHDMSFZCZOZPG-UHFFFAOYSA-N 2-bromo-1-(1h-indazol-6-yl)ethanone Chemical compound BrCC(=O)C1=CC=C2C=NNC2=C1 LAHDMSFZCZOZPG-UHFFFAOYSA-N 0.000 description 1
• NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
• AYPSHJCKSDNETA-UHFFFAOYSA-N 2-chloro-1h-benzimidazole Chemical compound C1=CC=C2NC(Cl)=NC2=C1 AYPSHJCKSDNETA-UHFFFAOYSA-N 0.000 description 1
• KQOOFMWRLDRDAX-UHFFFAOYSA-N 2-chloro-4-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1Cl KQOOFMWRLDRDAX-UHFFFAOYSA-N 0.000 description 1
• NHOKMZVDHBVHBY-UHFFFAOYSA-N 2-chloro-4-fluoro-n-(5-methyl-1h-indazol-6-yl)-5-nitrobenzamide Chemical compound CC1=CC=2C=NNC=2C=C1NC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1Cl NHOKMZVDHBVHBY-UHFFFAOYSA-N 0.000 description 1
• GRPWQLDSGNZEQE-UHFFFAOYSA-N 2-chloro-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1Cl GRPWQLDSGNZEQE-UHFFFAOYSA-N 0.000 description 1
• VFVHWCKUHAEDMY-UHFFFAOYSA-N 2-chloro-5-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(Cl)C(C=O)=C1 VFVHWCKUHAEDMY-UHFFFAOYSA-N 0.000 description 1
• GWSMACGSFHRVFA-UHFFFAOYSA-N 2-chloro-6-nitro-1h-benzimidazole Chemical compound [O-][N+](=O)C1=CC=C2N=C(Cl)NC2=C1 GWSMACGSFHRVFA-UHFFFAOYSA-N 0.000 description 1
• FXVOABRTUMJHKW-UHFFFAOYSA-N 2-chloro-N-(1H-indazol-6-yl)-5-nitrobenzamide Chemical compound ClC1=C(C(=O)NC2=CC=C3C=NNC3=C2)C=C(C=C1)[N+](=O)[O-] FXVOABRTUMJHKW-UHFFFAOYSA-N 0.000 description 1
• CDEGDZUMZIYNRD-UHFFFAOYSA-N 2-cyclohexylaniline Chemical compound NC1=CC=CC=C1C1CCCCC1 CDEGDZUMZIYNRD-UHFFFAOYSA-N 0.000 description 1
• UKPLRVAKKXWITN-UHFFFAOYSA-N 2-cyclopentylethanamine Chemical compound NCCC1CCCC1 UKPLRVAKKXWITN-UHFFFAOYSA-N 0.000 description 1
• UXBIHGQYRYAMFN-UHFFFAOYSA-N 2-fluoro-4-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=C(C#N)C(F)=C1 UXBIHGQYRYAMFN-UHFFFAOYSA-N 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• AJNOGKRGWMABSP-UHFFFAOYSA-N 2-isothiocyanato-1-(thietan-3-yl)imidazole Chemical compound S=C=NC1=NC=CN1C1CSC1 AJNOGKRGWMABSP-UHFFFAOYSA-N 0.000 description 1
• WRYUAWPDMHAHSE-UHFFFAOYSA-N 2-isothiocyanato-1-propan-2-ylimidazole Chemical compound CC(C)N1C=CN=C1N=C=S WRYUAWPDMHAHSE-UHFFFAOYSA-N 0.000 description 1
• WFJPRCMYUOOTNS-UHFFFAOYSA-N 2-isothiocyanatopyridine Chemical compound S=C=NC1=CC=CC=N1 WFJPRCMYUOOTNS-UHFFFAOYSA-N 0.000 description 1
• NJBCRXCAPCODGX-UHFFFAOYSA-N 2-methyl-n-(2-methylpropyl)propan-1-amine Chemical compound CC(C)CNCC(C)C NJBCRXCAPCODGX-UHFFFAOYSA-N 0.000 description 1
• BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
• DWKHLNTXRMLLEJ-UHFFFAOYSA-N 2-n-cyclopentylbenzene-1,2-diamine Chemical compound NC1=CC=CC=C1NC1CCCC1 DWKHLNTXRMLLEJ-UHFFFAOYSA-N 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• BFEDTJYWENCTKG-UHFFFAOYSA-N 2-nitro-1-(thietan-3-yl)imidazole Chemical compound [O-][N+](=O)C1=NC=CN1C1CSC1 BFEDTJYWENCTKG-UHFFFAOYSA-N 0.000 description 1
• ZXSMRFRGMRPZEG-UHFFFAOYSA-N 2-nitro-1-propan-2-ylimidazole Chemical compound CC(C)N1C=CN=C1[N+]([O-])=O ZXSMRFRGMRPZEG-UHFFFAOYSA-N 0.000 description 1
• HQMMOSQFCNKPFQ-UHFFFAOYSA-N 2-nitro-4-(2-trimethylsilylethynyl)aniline Chemical compound C[Si](C)(C)C#CC1=CC=C(N)C([N+]([O-])=O)=C1 HQMMOSQFCNKPFQ-UHFFFAOYSA-N 0.000 description 1
• IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• XSFHICWNEBCMNN-UHFFFAOYSA-N 2h-benzotriazol-5-amine Chemical compound NC1=CC=C2NN=NC2=C1 XSFHICWNEBCMNN-UHFFFAOYSA-N 0.000 description 1
• HEMGYNNCNNODNX-UHFFFAOYSA-N 3,4-diaminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1N HEMGYNNCNNODNX-UHFFFAOYSA-N 0.000 description 1
• JBRNKCVWLAVFHO-UHFFFAOYSA-N 3-(1,3-benzothiazol-5-yl)-2-chloro-4-fluoro-5-nitrobenzamide Chemical compound NC(=O)C1=CC([N+]([O-])=O)=C(F)C(C=2C=C3N=CSC3=CC=2)=C1Cl JBRNKCVWLAVFHO-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• YJJMWJZZQCOQBW-UHFFFAOYSA-N 3-[2-(1H-indazol-6-yl)ethynyl]benzene-1,2-diamine Chemical compound N1N=CC2=CC=C(C=C12)C#CC1=C(C(=CC=C1)N)N YJJMWJZZQCOQBW-UHFFFAOYSA-N 0.000 description 1
• SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
• SRRZKFKXLGSCBC-UHFFFAOYSA-N 3-[[6-(1,3-benzothiazol-6-ylcarbamoyl)-5-(diethylamino)-1h-benzimidazol-2-yl]amino]benzoic acid Chemical compound N=1C=2C=C(C(=O)NC=3C=C4SC=NC4=CC=3)C(N(CC)CC)=CC=2NC=1NC1=CC=CC(C(O)=O)=C1 SRRZKFKXLGSCBC-UHFFFAOYSA-N 0.000 description 1
• YZAYFMIFAUUSQD-UHFFFAOYSA-N 3-amino-2-(3,5-dimethylpiperazin-1-yl)-N-(1H-indazol-6-yl)-5-nitrobenzamide Chemical compound NC=1C(=C(C(=O)NC2=CC=C3C=NNC3=C2)C=C(C=1)[N+](=O)[O-])N1CC(NC(C1)C)C YZAYFMIFAUUSQD-UHFFFAOYSA-N 0.000 description 1
• CMLQPGNXQCTQDS-UHFFFAOYSA-N 3-amino-2-chloro-n-(5-methyl-1h-indazol-6-yl)-5-nitrobenzamide Chemical compound CC1=CC=2C=NNC=2C=C1NC(=O)C1=CC([N+]([O-])=O)=CC(N)=C1Cl CMLQPGNXQCTQDS-UHFFFAOYSA-N 0.000 description 1
• HUZBMPGISFCWCM-UHFFFAOYSA-N 3-amino-N-(1,3-benzothiazol-6-yl)-5-nitro-2-piperazin-1-ylbenzamide Chemical compound NC=1C(=C(C(=O)NC2=CC3=C(N=CS3)C=C2)C=C(C=1)[N+](=O)[O-])N1CCNCC1 HUZBMPGISFCWCM-UHFFFAOYSA-N 0.000 description 1
• ZKLRKPJSKHWSJL-UHFFFAOYSA-N 3-amino-N-(1H-indazol-6-yl)-5-nitro-2-(propylamino)benzamide Chemical compound NC=1C(=C(C(=O)NC2=CC=C3C=NNC3=C2)C=C(C=1)[N+](=O)[O-])NCCC ZKLRKPJSKHWSJL-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
• ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
• DRRARKIFTNKQDW-UHFFFAOYSA-N 3-chloro-2h-indazol-6-amine Chemical compound C1=C(N)C=CC2=C(Cl)NN=C21 DRRARKIFTNKQDW-UHFFFAOYSA-N 0.000 description 1
• RZJPBQGRCNJYBU-UHFFFAOYSA-N 3-chloropyridin-2-amine Chemical compound NC1=NC=CC=C1Cl RZJPBQGRCNJYBU-UHFFFAOYSA-N 0.000 description 1
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
• UGMQFWDSELPKKP-UHFFFAOYSA-N 3-isothiocyanatoisoquinoline Chemical compound C1=CC=C2C=NC(N=C=S)=CC2=C1 UGMQFWDSELPKKP-UHFFFAOYSA-N 0.000 description 1
• OZYWKOVKYCUERD-UHFFFAOYSA-N 3-methoxy-6-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=C2C(OC)=NNC2=C1 OZYWKOVKYCUERD-UHFFFAOYSA-N 0.000 description 1
• PPFLOLZEHGQVQM-UHFFFAOYSA-N 3-methylthiophen-2-amine Chemical compound CC=1C=CSC=1N PPFLOLZEHGQVQM-UHFFFAOYSA-N 0.000 description 1
• SMLMEJBJLAFPGE-UHFFFAOYSA-N 3-n-(2-morpholin-4-ylethyl)-1h-indazole-3,6-diamine Chemical compound N=1NC2=CC(N)=CC=C2C=1NCCN1CCOCC1 SMLMEJBJLAFPGE-UHFFFAOYSA-N 0.000 description 1
• KWAYEPXDGHYGRW-UHFFFAOYSA-N 3-nitrobenzamide Chemical compound NC(=O)C1=CC=CC([N+]([O-])=O)=C1 KWAYEPXDGHYGRW-UHFFFAOYSA-N 0.000 description 1
• WFRXSXUDWCVSPI-UHFFFAOYSA-N 3h-benzimidazol-5-amine Chemical compound NC1=CC=C2NC=NC2=C1 WFRXSXUDWCVSPI-UHFFFAOYSA-N 0.000 description 1
• BFPFJEJVHNCEHJ-UHFFFAOYSA-N 4,5-diamino-2-(3,5-dimethylpiperazin-1-yl)-n-(1h-indazol-6-yl)benzamide Chemical compound C1C(C)NC(C)CN1C1=CC(N)=C(N)C=C1C(=O)NC1=CC=C(C=NN2)C2=C1 BFPFJEJVHNCEHJ-UHFFFAOYSA-N 0.000 description 1
• VXTHHSMHDOTXLI-UHFFFAOYSA-N 4,5-diamino-2-(dimethylamino)-n-(1h-indazol-6-yl)benzamide Chemical compound CN(C)C1=CC(N)=C(N)C=C1C(=O)NC1=CC=C(C=NN2)C2=C1 VXTHHSMHDOTXLI-UHFFFAOYSA-N 0.000 description 1
• RDNFDBYFURWQQA-UHFFFAOYSA-N 4,5-diamino-2-chloro-n-(1h-indazol-6-yl)benzamide Chemical compound C1=C(N)C(N)=CC(Cl)=C1C(=O)NC1=CC=C(C=NN2)C2=C1 RDNFDBYFURWQQA-UHFFFAOYSA-N 0.000 description 1
• MKIQFXJFIRECDR-UHFFFAOYSA-N 4,5-diamino-n-(1,3-benzothiazol-6-yl)-2-(4-methylpiperazin-1-yl)benzamide Chemical compound C1CN(C)CCN1C1=CC(N)=C(N)C=C1C(=O)NC1=CC=C(N=CS2)C2=C1 MKIQFXJFIRECDR-UHFFFAOYSA-N 0.000 description 1
• OOTPJJBDKHDSSL-UHFFFAOYSA-N 4,5-diamino-n-(1,3-benzothiazol-6-yl)-2-(diethylamino)benzamide Chemical compound CCN(CC)C1=CC(N)=C(N)C=C1C(=O)NC1=CC=C(N=CS2)C2=C1 OOTPJJBDKHDSSL-UHFFFAOYSA-N 0.000 description 1
• OUXKHEZFDPFKLE-UHFFFAOYSA-N 4,5-diamino-n-(1h-indazol-5-yl)-2-morpholin-4-ylbenzamide Chemical compound C=1C=C2NN=CC2=CC=1NC(=O)C=1C=C(N)C(N)=CC=1N1CCOCC1 OUXKHEZFDPFKLE-UHFFFAOYSA-N 0.000 description 1
• JNCJUTHVKOYGDC-UHFFFAOYSA-N 4,5-diamino-n-(1h-indazol-6-yl)-2-(propylamino)benzamide Chemical compound CCCNC1=CC(N)=C(N)C=C1C(=O)NC1=CC=C(C=NN2)C2=C1 JNCJUTHVKOYGDC-UHFFFAOYSA-N 0.000 description 1
• HMHPQTZFJSVCAG-UHFFFAOYSA-N 4-(1h-indazol-6-yloxy)benzene-1,2-diamine Chemical compound C1=C(N)C(N)=CC=C1OC1=CC=C(C=NN2)C2=C1 HMHPQTZFJSVCAG-UHFFFAOYSA-N 0.000 description 1
• VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
• KEZIZFAGXKFDBW-UHFFFAOYSA-N 4-[(6-nitro-2h-indazol-3-yl)methyl]morpholine Chemical compound N=1NC2=CC([N+](=O)[O-])=CC=C2C=1CN1CCOCC1 KEZIZFAGXKFDBW-UHFFFAOYSA-N 0.000 description 1
• ROAFBHQSUYXJKY-UHFFFAOYSA-N 4-[2-[(6-nitro-1h-indazol-3-yl)oxy]ethyl]morpholine Chemical compound N=1NC2=CC([N+](=O)[O-])=CC=C2C=1OCCN1CCOCC1 ROAFBHQSUYXJKY-UHFFFAOYSA-N 0.000 description 1
• QMGPOYUVIYLZPP-UHFFFAOYSA-N 4-[5-(1h-indazol-6-yl)-1h-imidazol-2-yl]-2-nitroaniline Chemical compound C1=C([N+]([O-])=O)C(N)=CC=C1C1=NC=C(C=2C=C3NN=CC3=CC=2)N1 QMGPOYUVIYLZPP-UHFFFAOYSA-N 0.000 description 1
• PEQZYZISBDCUOA-UHFFFAOYSA-N 4-amino-2-(dimethylamino)-n-(1h-indazol-6-yl)-5-nitrobenzamide Chemical compound CN(C)C1=CC(N)=C([N+]([O-])=O)C=C1C(=O)NC1=CC=C(C=NN2)C2=C1 PEQZYZISBDCUOA-UHFFFAOYSA-N 0.000 description 1
• YGSUGPCIPQMVCA-UHFFFAOYSA-N 4-amino-2-[bis(2-methylpropyl)amino]-n-(1h-indazol-6-yl)-5-nitrobenzamide Chemical compound CC(C)CN(CC(C)C)C1=CC(N)=C([N+]([O-])=O)C=C1C(=O)NC1=CC=C(C=NN2)C2=C1 YGSUGPCIPQMVCA-UHFFFAOYSA-N 0.000 description 1
• LKUQSULKYZJREJ-UHFFFAOYSA-N 4-amino-n-(1,3-benzothiazol-6-yl)-2-(4-methylpiperazin-1-yl)-5-nitrobenzamide Chemical compound C1CN(C)CCN1C1=CC(N)=C([N+]([O-])=O)C=C1C(=O)NC1=CC=C(N=CS2)C2=C1 LKUQSULKYZJREJ-UHFFFAOYSA-N 0.000 description 1
• RRALXWMDLUAYQM-UHFFFAOYSA-N 4-amino-n-(1h-indazol-5-yl)-2-(4-methylpiperazin-1-yl)-5-nitrobenzamide Chemical compound C1CN(C)CCN1C1=CC(N)=C([N+]([O-])=O)C=C1C(=O)NC1=CC=C(NN=C2)C2=C1 RRALXWMDLUAYQM-UHFFFAOYSA-N 0.000 description 1
• YLCOKDQFUKUTIN-UHFFFAOYSA-N 4-amino-n-(1h-indazol-6-yl)-2-(4-methylpiperazin-1-yl)-5-nitrobenzamide Chemical compound C1CN(C)CCN1C1=CC(N)=C([N+]([O-])=O)C=C1C(=O)NC1=CC=C(C=NN2)C2=C1 YLCOKDQFUKUTIN-UHFFFAOYSA-N 0.000 description 1
• UDZCXRVUWCZENR-UHFFFAOYSA-N 4-amino-n-(1h-indazol-6-yl)-3-nitrobenzamide Chemical compound C1=C([N+]([O-])=O)C(N)=CC=C1C(=O)NC1=CC=C(C=NN2)C2=C1 UDZCXRVUWCZENR-UHFFFAOYSA-N 0.000 description 1
• QRZMXADUXZADTF-UHFFFAOYSA-N 4-aminoimidazole Chemical compound NC1=CNC=N1 QRZMXADUXZADTF-UHFFFAOYSA-N 0.000 description 1
• ZCWBZRBJSPWUPG-UHFFFAOYSA-N 4-bromo-2-nitroaniline Chemical compound NC1=CC=C(Br)C=C1[N+]([O-])=O ZCWBZRBJSPWUPG-UHFFFAOYSA-N 0.000 description 1
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
• VCFHQBXACYIBGV-UHFFFAOYSA-N 4-hydroxy-n-(1h-indazol-6-yl)-3-nitrobenzamide Chemical compound C1=C([N+]([O-])=O)C(O)=CC=C1C(=O)NC1=CC=C(C=NN2)C2=C1 VCFHQBXACYIBGV-UHFFFAOYSA-N 0.000 description 1
• 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
• VTDOEFXTVHCAAM-UHFFFAOYSA-N 4-methylpent-3-ene-1,2,3-triol Chemical compound CC(C)=C(O)C(O)CO VTDOEFXTVHCAAM-UHFFFAOYSA-N 0.000 description 1
• KRSSUWCDMVEPLI-UHFFFAOYSA-N 5,6,7,8-tetrahydro-1h-imidazo[4,5-h][1,4]benzodiazepin-9-one Chemical compound C1=C2C(=O)NCCNC2=CC2=C1N=CN2 KRSSUWCDMVEPLI-UHFFFAOYSA-N 0.000 description 1
• JPUYXUBUJJDJNL-UHFFFAOYSA-N 5-amino-1,3-dihydroindol-2-one Chemical compound NC1=CC=C2NC(=O)CC2=C1 JPUYXUBUJJDJNL-UHFFFAOYSA-N 0.000 description 1
• 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
• WFMLWPRGJHUSEX-UHFFFAOYSA-N 5-methyl-1h-indazol-6-amine Chemical compound C1=C(N)C(C)=CC2=C1NN=C2 WFMLWPRGJHUSEX-UHFFFAOYSA-N 0.000 description 1
• AZWAXIMNWVYSMP-UHFFFAOYSA-N 5-methyl-6-nitro-1h-indazole Chemical compound C1=C([N+]([O-])=O)C(C)=CC2=C1NN=C2 AZWAXIMNWVYSMP-UHFFFAOYSA-N 0.000 description 1
• YYDFLBVFORDXNF-UHFFFAOYSA-N 6-(3-chloro-4-nitrophenoxy)-1h-indazole Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC=C1OC1=CC=C(C=NN2)C2=C1 YYDFLBVFORDXNF-UHFFFAOYSA-N 0.000 description 1
• VYWTUAVOPRJLJQ-UHFFFAOYSA-N 6-(4-aminopiperidin-1-yl)-n-(1h-indazol-6-yl)-2-[(3-methylpyridin-2-yl)amino]-3h-benzimidazole-5-carboxamide Chemical compound CC1=CC=CN=C1NC1=NC2=CC(C(=O)NC=3C=C4NN=CC4=CC=3)=C(N3CCC(N)CC3)C=C2N1 VYWTUAVOPRJLJQ-UHFFFAOYSA-N 0.000 description 1
• DGFDADDBVBAADX-UHFFFAOYSA-N 6-(4-aminopiperidin-1-yl)-n-(1h-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound C1CC(N)CCN1C(C(=C1)C(=O)NC=2C=C3NN=CC3=CC=2)=CC2=C1N=C(NC=1C(=CC=CC=1)C(F)(F)F)N2 DGFDADDBVBAADX-UHFFFAOYSA-N 0.000 description 1
• BSJALJDGTYIXOY-UHFFFAOYSA-N 6-(diethylamino)-2-(propan-2-ylamino)-3h-benzimidazole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C(N(CC)CC)=CC2=C1N=C(NC(C)C)N2 BSJALJDGTYIXOY-UHFFFAOYSA-N 0.000 description 1
• WFKBDVICDXSCBN-UHFFFAOYSA-N 6-(dimethylamino)-n-(1h-indazol-6-yl)-2-[(3-methylpyridin-2-yl)amino]-3h-benzimidazole-5-carboxamide Chemical compound N=1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(N(C)C)=CC=2NC=1NC1=NC=CC=C1C WFKBDVICDXSCBN-UHFFFAOYSA-N 0.000 description 1
• CWMLARGLZYFTJP-UHFFFAOYSA-N 6-(dipropylamino)-N-(1H-indazol-6-yl)-2-[(3-methylpyridin-2-yl)amino]-3H-benzimidazole-5-carboxamide Chemical compound CCCN(CCC)c1cc2[nH]c(Nc3ncccc3C)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 CWMLARGLZYFTJP-UHFFFAOYSA-N 0.000 description 1
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
• QAPVVRVSMQUUPN-UHFFFAOYSA-N 6-[2-(1h-indazol-6-yl)ethynyl]-n-[2-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound FC(F)(F)C1=CC=CC=C1NC1=NC2=CC(C#CC=3C=C4NN=CC4=CC=3)=CC=C2N1 QAPVVRVSMQUUPN-UHFFFAOYSA-N 0.000 description 1
• JROPHUYSNXWRLV-UHFFFAOYSA-N 6-[4-(dimethylamino)piperidin-1-yl]-n-(1h-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound C1CC(N(C)C)CCN1C(C(=C1)C(=O)NC=2C=C3NN=CC3=CC=2)=CC2=C1NC(NC=1C(=CC=CC=1)C(F)(F)F)=N2 JROPHUYSNXWRLV-UHFFFAOYSA-N 0.000 description 1
• UPUZFYDYADSBFR-UHFFFAOYSA-N 6-[ethyl(propyl)amino]-N-(1H-indazol-6-yl)-2-[(3-methylpyridin-2-yl)amino]-3H-benzimidazole-5-carboxamide Chemical compound CCCN(CC)c1cc2[nH]c(Nc3ncccc3C)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 UPUZFYDYADSBFR-UHFFFAOYSA-N 0.000 description 1
• HKKPGPCUDCXJNH-UHFFFAOYSA-N 6-[ethyl(propyl)amino]-N-(1H-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-3H-benzimidazole-5-carboxamide Chemical compound CCCN(CC)c1cc2[nH]c(Nc3ccccc3C(F)(F)F)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 HKKPGPCUDCXJNH-UHFFFAOYSA-N 0.000 description 1
• HWDYZCMLHLQBSP-UHFFFAOYSA-N 6-imidazol-1-yl-n-(1h-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1NC1=NC2=CC(N3C=NC=C3)=C(C(=O)NC=3C=C4NN=CC4=CC=3)C=C2N1 HWDYZCMLHLQBSP-UHFFFAOYSA-N 0.000 description 1
• GUQMGUUEHIUELS-UHFFFAOYSA-N 6-nitro-1h-indazol-3-amine Chemical compound [O-][N+](=O)C1=CC=C2C(N)=NNC2=C1 GUQMGUUEHIUELS-UHFFFAOYSA-N 0.000 description 1
• PBBKQKPSEOWXDT-UHFFFAOYSA-N 6-nitro-n-(2-propan-2-ylphenyl)-1h-benzimidazol-2-amine Chemical compound CC(C)C1=CC=CC=C1NC1=NC2=CC([N+]([O-])=O)=CC=C2N1 PBBKQKPSEOWXDT-UHFFFAOYSA-N 0.000 description 1
• QRYSWXFQLFLJTC-UHFFFAOYSA-N 616-82-0 Chemical compound OC(=O)C1=CC=C(O)C([N+]([O-])=O)=C1 QRYSWXFQLFLJTC-UHFFFAOYSA-N 0.000 description 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
• APMPQGGQQHXECK-UHFFFAOYSA-N 8-amino-1-ethyl-4-(1h-indazol-6-yl)-7-nitro-2,3-dihydro-1,4-benzodiazepin-5-one Chemical compound O=C1C2=CC([N+]([O-])=O)=C(N)C=C2N(CC)CCN1C1=CC=C(C=NN2)C2=C1 APMPQGGQQHXECK-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 108090000461 Aurora Kinase A Proteins 0.000 description 1
• 102000042871 Aurora family Human genes 0.000 description 1
• 108091082291 Aurora family Proteins 0.000 description 1
• 102100032311 Aurora kinase A Human genes 0.000 description 1
• 102100032306 Aurora kinase B Human genes 0.000 description 1
• 108090000749 Aurora kinase B Proteins 0.000 description 1
• 102100026630 Aurora kinase C Human genes 0.000 description 1
• 108090000805 Aurora kinase C Proteins 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 208000004860 Blast Crisis Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 206010055113 Breast cancer metastatic Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• JQPWHPNVUPHRFJ-UHFFFAOYSA-N CC(=O)Nc1n[nH]c2cc(NC(=O)c3ccc4[nH]c(Nc5ccccn5)nc4c3)ccc12 Chemical compound CC(=O)Nc1n[nH]c2cc(NC(=O)c3ccc4[nH]c(Nc5ccccn5)nc4c3)ccc12 JQPWHPNVUPHRFJ-UHFFFAOYSA-N 0.000 description 1
• YEHGALLUQFPTDK-UHFFFAOYSA-N CC(C)N1CCN(CC1)c1ccccc1C(N)=O Chemical compound CC(C)N1CCN(CC1)c1ccccc1C(N)=O YEHGALLUQFPTDK-UHFFFAOYSA-N 0.000 description 1
• IYHUJCAONMPBNA-UHFFFAOYSA-N CCCN(CCC)c1cc2[nH]c(Nc3ccccc3C(F)(F)F)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 Chemical compound CCCN(CCC)c1cc2[nH]c(Nc3ccccc3C(F)(F)F)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 IYHUJCAONMPBNA-UHFFFAOYSA-N 0.000 description 1
• NCKUCJQAYZNZDP-UHFFFAOYSA-N CN(CC1)CCN1C(C(C(O)=O)=C1)=CC2=C1N=C(N)N2.NC1=CC=C(C=NN2)C2=C1 Chemical compound CN(CC1)CCN1C(C(C(O)=O)=C1)=CC2=C1N=C(N)N2.NC1=CC=C(C=NN2)C2=C1 NCKUCJQAYZNZDP-UHFFFAOYSA-N 0.000 description 1
• RWPBFNLGWIMRAW-UHFFFAOYSA-N CN1N=CC2=CC(=CC=C12)NC(=O)C1=CC2=C(N=C(N2)NC2=C(C=C(C=C2)Cl)Cl)C=C1.N1N=NC2=C1C=CC(=C2)NC(=O)C2=CC1=C(NC(=N1)NC1=NC=CC=C1)C=C2 Chemical compound CN1N=CC2=CC(=CC=C12)NC(=O)C1=CC2=C(N=C(N2)NC2=C(C=C(C=C2)Cl)Cl)C=C1.N1N=NC2=C1C=CC(=C2)NC(=O)C2=CC1=C(NC(=N1)NC1=NC=CC=C1)C=C2 RWPBFNLGWIMRAW-UHFFFAOYSA-N 0.000 description 1
• FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• YDIPDHILIPMVIK-UHFFFAOYSA-N Cc1c(Cl)cccc1Nc1nc2ccc(cc2[nH]1)C(=O)Nc1ccc2cn[nH]c2c1 Chemical compound Cc1c(Cl)cccc1Nc1nc2ccc(cc2[nH]1)C(=O)Nc1ccc2cn[nH]c2c1 YDIPDHILIPMVIK-UHFFFAOYSA-N 0.000 description 1
• 108010076303 Centromere Protein A Proteins 0.000 description 1
• 102000011682 Centromere Protein A Human genes 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000037051 Chromosomal Instability Diseases 0.000 description 1
• IZVSKUVTFPRSEW-UHFFFAOYSA-N Cl.Cl.Cl.S1C=NC2=C1C=C(C=C2)NC(=O)C2=CC1=C(N=CN1)C=C2 Chemical compound Cl.Cl.Cl.S1C=NC2=C1C=C(C=C2)NC(=O)C2=CC1=C(N=CN1)C=C2 IZVSKUVTFPRSEW-UHFFFAOYSA-N 0.000 description 1
• HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
• DUMRNDCZYNGEIU-UHFFFAOYSA-N Clc1ccc(Nc2nc3ccc(cc3[nH]2)C(=O)Nc2ccc3[nH]nnc3c2)c(Cl)c1 Chemical compound Clc1ccc(Nc2nc3ccc(cc3[nH]2)C(=O)Nc2ccc3[nH]nnc3c2)c(Cl)c1 DUMRNDCZYNGEIU-UHFFFAOYSA-N 0.000 description 1
• HTOFCVRCYNPIOT-UHFFFAOYSA-N Clc1ccc(Nc2nc3ccc(cc3[nH]2)C(=O)Nc2ccc3cn[nH]c3c2)cc1 Chemical compound Clc1ccc(Nc2nc3ccc(cc3[nH]2)C(=O)Nc2ccc3cn[nH]c3c2)cc1 HTOFCVRCYNPIOT-UHFFFAOYSA-N 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 102100030011 Endoribonuclease Human genes 0.000 description 1
• 101710199605 Endoribonuclease Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• IFAAOFLNEKINSP-UHFFFAOYSA-N FC(F)(F)c1ccccc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCCC1 Chemical compound FC(F)(F)c1ccccc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCCC1 IFAAOFLNEKINSP-UHFFFAOYSA-N 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
• 230000010337 G2 phase Effects 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 241000282575 Gorilla Species 0.000 description 1
• 206010053759 Growth retardation Diseases 0.000 description 1
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000830894 Homo sapiens Targeting protein for Xklp2 Proteins 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 101000957678 Mus musculus Cytochrome P450 7B1 Proteins 0.000 description 1
• 102000005640 Myosin Type II Human genes 0.000 description 1
• 108010045128 Myosin Type II Proteins 0.000 description 1
• NDBVDNCHYRHPQH-UHFFFAOYSA-N N-(1,3-benzothiazol-6-yl)-6-(diethylamino)-2-(2,5-difluoroanilino)-3H-benzimidazole-5-carboxamide Chemical compound CCN(CC)c1cc2nc(Nc3cc(F)ccc3F)[nH]c2cc1C(=O)Nc1ccc2ncsc2c1 NDBVDNCHYRHPQH-UHFFFAOYSA-N 0.000 description 1
• PBFMYGSTGMLAQB-UHFFFAOYSA-N N-(1,3-benzothiazol-6-yl)-6-piperazin-1-yl-2-[2-(trifluoromethyl)anilino]-3H-benzimidazole-5-carboxamide trihydrochloride Chemical compound Cl.Cl.Cl.FC(F)(F)C1=CC=CC=C1NC1=NC2=CC(C(=O)NC=3C=C4SC=NC4=CC=3)=C(N3CCNCC3)C=C2N1 PBFMYGSTGMLAQB-UHFFFAOYSA-N 0.000 description 1
• GOCYJOPWZVUUCA-UHFFFAOYSA-N N-(1-methylindazol-5-yl)-2-(pyridin-2-ylamino)-3H-benzimidazole-5-carboxamide Chemical compound Cn1ncc2cc(NC(=O)c3ccc4[nH]c(Nc5ccccn5)nc4c3)ccc12 GOCYJOPWZVUUCA-UHFFFAOYSA-N 0.000 description 1
• VXXOLWHYQNIPPY-UHFFFAOYSA-N N-(1H-indazol-5-yl)-2-(isoquinolin-3-ylamino)-3H-benzimidazole-5-carboxamide Chemical compound O=C(Nc1ccc2[nH]ncc2c1)c1ccc2[nH]c(Nc3cc4ccccc4cn3)nc2c1 VXXOLWHYQNIPPY-UHFFFAOYSA-N 0.000 description 1
• OGGJOXITOBBAGT-UHFFFAOYSA-N N-(1H-indazol-6-yl)-2-(1,3-thiazol-2-ylamino)-3H-benzimidazole-5-carboxamide Chemical compound O=C(Nc1ccc2cn[nH]c2c1)c1ccc2[nH]c(Nc3nccs3)nc2c1 OGGJOXITOBBAGT-UHFFFAOYSA-N 0.000 description 1
• AASSLSRBWMWRJT-UHFFFAOYSA-N N-(1H-indazol-6-yl)-2-(2-phenylanilino)-3H-benzimidazole-5-carboxamide Chemical compound O=C(Nc1ccc2cn[nH]c2c1)c1ccc2nc(Nc3ccccc3-c3ccccc3)[nH]c2c1 AASSLSRBWMWRJT-UHFFFAOYSA-N 0.000 description 1
• OXCKEWZFPUGFKD-UHFFFAOYSA-N N-(1H-indazol-6-yl)-2-(2-propan-2-ylanilino)-3H-benzimidazole-5-carboxamide Chemical compound CC(C)c1ccccc1Nc1nc2ccc(cc2[nH]1)C(=O)Nc1ccc2cn[nH]c2c1 OXCKEWZFPUGFKD-UHFFFAOYSA-N 0.000 description 1
• OQCUTJAZBIHUMJ-UHFFFAOYSA-N N-(1H-indazol-6-yl)-2-(naphthalen-1-ylamino)-3H-benzimidazole-5-carboxamide Chemical compound O=C(Nc1ccc2cn[nH]c2c1)c1ccc2nc(Nc3cccc4ccccc34)[nH]c2c1 OQCUTJAZBIHUMJ-UHFFFAOYSA-N 0.000 description 1
• LUPNKJNUEJCCSR-UHFFFAOYSA-N N-(1H-indazol-6-yl)-2-[(3-methylpyridin-2-yl)amino]-6-pyrrolidin-1-yl-3H-benzimidazole-5-carboxamide Chemical compound Cc1cccnc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCCC1 LUPNKJNUEJCCSR-UHFFFAOYSA-N 0.000 description 1
• CEJIKJXISWFZPL-UHFFFAOYSA-N N-(1H-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-2-(1,3-thiazol-2-ylamino)-3H-benzimidazole-5-carboxamide Chemical compound CN1CCN(CC1)c1cc2[nH]c(Nc3nccs3)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 CEJIKJXISWFZPL-UHFFFAOYSA-N 0.000 description 1
• BGZNNNSDCWMGML-UHFFFAOYSA-N N-(1H-indazol-6-yl)-6-(4-propan-2-ylpiperazin-1-yl)-2-[2-(trifluoromethyl)anilino]-3H-benzimidazole-5-carboxamide Chemical compound CC(C)N1CCN(CC1)c1cc2[nH]c(Nc3ccccc3C(F)(F)F)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 BGZNNNSDCWMGML-UHFFFAOYSA-N 0.000 description 1
• JZHNRKYOHOZXHP-UHFFFAOYSA-N N-(3-benzamido-1H-indazol-5-yl)-2-(2,4-dichloroanilino)-3H-benzimidazole-5-carboxamide Chemical compound Clc1ccc(Nc2nc3ccc(cc3[nH]2)C(=O)Nc2ccc3[nH]nc(NC(=O)c4ccccc4)c3c2)c(Cl)c1 JZHNRKYOHOZXHP-UHFFFAOYSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• YURFEUFQKRDIIC-UHFFFAOYSA-N N1=C(C=CC=C1)NC1=NC2=C(N1)C=CC(=C2)C(=O)O.N2N=CC1=CC(=CC=C21)NC(=O)C2=CC1=C(NC(=N1)NC1=NC=CC=C1)C=C2 Chemical compound N1=C(C=CC=C1)NC1=NC2=C(N1)C=CC(=C2)C(=O)O.N2N=CC1=CC(=CC=C21)NC(=O)C2=CC1=C(NC(=N1)NC1=NC=CC=C1)C=C2 YURFEUFQKRDIIC-UHFFFAOYSA-N 0.000 description 1
• LRMICGATKRUJIJ-UHFFFAOYSA-N N1N=CC2=CC=C(C=C12)NC(=O)C1=CC2=C(NC(=N2)NC2=C(C=CC=C2F)F)C=C1N(CC)CC Chemical compound N1N=CC2=CC=C(C=C12)NC(=O)C1=CC2=C(NC(=N2)NC2=C(C=CC=C2F)F)C=C1N(CC)CC LRMICGATKRUJIJ-UHFFFAOYSA-N 0.000 description 1
• SCJHXXWTPFJORA-WWMYMODYSA-N N1N=CC2=CC=C(C=C12)NC(=O)C1=CC2=C(NC(=N2)N[C@@H]2[C@H]3CC[C@@H](C2)C3)C=C1N1CCN(CC1)C Chemical compound N1N=CC2=CC=C(C=C12)NC(=O)C1=CC2=C(NC(=N2)N[C@@H]2[C@H]3CC[C@@H](C2)C3)C=C1N1CCN(CC1)C SCJHXXWTPFJORA-WWMYMODYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 102100024007 Neurofilament heavy polypeptide Human genes 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• IEWCMVWDHDKZMP-UHFFFAOYSA-N O=C(Nc1ccc2cn[nH]c2c1)c1ccc2[nH]c(Nc3nc(cs3)-c3ccccc3)nc2c1 Chemical compound O=C(Nc1ccc2cn[nH]c2c1)c1ccc2[nH]c(Nc3nc(cs3)-c3ccccc3)nc2c1 IEWCMVWDHDKZMP-UHFFFAOYSA-N 0.000 description 1
• UYCMLDDGQAMGQI-UHFFFAOYSA-N O=C(Nc1ccc2cn[nH]c2c1)c1ccc2nc(Nc3nccn3C3CCCC3)[nH]c2c1 Chemical compound O=C(Nc1ccc2cn[nH]c2c1)c1ccc2nc(Nc3nccn3C3CCCC3)[nH]c2c1 UYCMLDDGQAMGQI-UHFFFAOYSA-N 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• 208000022873 Ocular disease Diseases 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 102000005569 Protein Phosphatase 1 Human genes 0.000 description 1
• 108010059000 Protein Phosphatase 1 Proteins 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 101000957679 Rattus norvegicus 25-hydroxycholesterol 7-alpha-hydroxylase Proteins 0.000 description 1
• 208000009527 Refractory anemia Diseases 0.000 description 1
• 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
• PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
• 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
• 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• CWNMCXYWPPLWDM-UHFFFAOYSA-N S1C=NC2=C1C=C(C=C2)NC(=O)C2=CC=CC=1NC(=NC12)NC1=NC=CC=C1.N1N=CC2=CC=C(C=C12)NC(=O)C1=CC2=C(NC(=N2)NC=2C=NC=CC2)C=C1 Chemical compound S1C=NC2=C1C=C(C=C2)NC(=O)C2=CC=CC=1NC(=NC12)NC1=NC=CC=C1.N1N=CC2=CC=C(C=C12)NC(=O)C1=CC2=C(NC(=N2)NC=2C=NC=CC2)C=C1 CWNMCXYWPPLWDM-UHFFFAOYSA-N 0.000 description 1
• 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 229920002253 Tannate Polymers 0.000 description 1
• 102100024813 Targeting protein for Xklp2 Human genes 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 150000008043 acidic salts Chemical class 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 125000004423 acyloxy group Chemical group 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 208000030002 adult glioblastoma Diseases 0.000 description 1
• 239000012996 alamarblue reagent Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000002723 alicyclic group Chemical group 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 125000003302 alkenyloxy group Chemical group 0.000 description 1
• 125000005136 alkenylsulfinyl group Chemical group 0.000 description 1
• 125000005137 alkenylsulfonyl group Chemical group 0.000 description 1
• 150000004703 alkoxides Chemical class 0.000 description 1
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
• 125000002877 alkyl aryl group Chemical group 0.000 description 1
• 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 125000005218 alkyleneheteroaryl group Chemical group 0.000 description 1
• 125000005133 alkynyloxy group Chemical group 0.000 description 1
• 125000005134 alkynylsulfinyl group Chemical group 0.000 description 1
• 125000005139 alkynylsulfonyl group Chemical group 0.000 description 1
• IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 238000003782 apoptosis assay Methods 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 125000003435 aroyl group Chemical group 0.000 description 1
• 125000005333 aroyloxy group Chemical group 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 150000007980 azole derivatives Chemical class 0.000 description 1
• 229910052788 barium Inorganic materials 0.000 description 1
• DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
• 150000001555 benzenes Chemical group 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 125000004540 benzothiazol-5-yl group Chemical group S1C=NC2=C1C=CC(=C2)* 0.000 description 1
• PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 201000011529 cardiovascular cancer Diseases 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 210000003793 centrosome Anatomy 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 229960002242 chlorocresol Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000024321 chromosome segregation Effects 0.000 description 1
• 229940114081 cinnamate Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 229940090805 clavulanate Drugs 0.000 description 1
• HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 201000010989 colorectal carcinoma Diseases 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 230000021953 cytokinesis Effects 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
• ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
• VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 150000004862 dioxolanes Chemical class 0.000 description 1
• MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
• 239000001177 diphosphate Substances 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000004821 distillation Methods 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• 229940088679 drug related substance Drugs 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 229940009662 edetate Drugs 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 229950005627 embonate Drugs 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 229950000206 estolate Drugs 0.000 description 1
• 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 235000008191 folinic acid Nutrition 0.000 description 1
• 239000011672 folinic acid Substances 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
• 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 229960001731 gluceptate Drugs 0.000 description 1
• KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 229940049906 glutamate Drugs 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 231100000001 growth retardation Toxicity 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 125000000262 haloalkenyl group Chemical group 0.000 description 1
• 125000004438 haloalkoxy group Chemical group 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
• 150000007857 hydrazones Chemical class 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• 229960003685 imatinib mesylate Drugs 0.000 description 1
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 229910001504 inorganic chloride Inorganic materials 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
• 229960000367 inositol Drugs 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• VYCKDIRCVDCQAE-UHFFFAOYSA-N isoquinolin-3-amine Chemical compound C1=CC=C2C=NC(N)=CC2=C1 VYCKDIRCVDCQAE-UHFFFAOYSA-N 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 235000015110 jellies Nutrition 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 229940099584 lactobionate Drugs 0.000 description 1
• JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 229960001691 leucovorin Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• TUSICEWIXLMXEY-UHFFFAOYSA-N methyl 1h-indazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=NNC2=C1 TUSICEWIXLMXEY-UHFFFAOYSA-N 0.000 description 1
• BWPCRFBKNZJREK-UHFFFAOYSA-N methyl 2-(2,4-dichloroanilino)-3h-benzimidazole-5-carboxylate Chemical compound N1C2=CC(C(=O)OC)=CC=C2N=C1NC1=CC=C(Cl)C=C1Cl BWPCRFBKNZJREK-UHFFFAOYSA-N 0.000 description 1
• OBSCTTXWWDCHAE-UHFFFAOYSA-N methyl 2-(2-ethylanilino)-3h-benzimidazole-5-carboxylate Chemical compound CCC1=CC=CC=C1NC1=NC2=CC=C(C(=O)OC)C=C2N1 OBSCTTXWWDCHAE-UHFFFAOYSA-N 0.000 description 1
• ZMHMODKLQDCJIY-UHFFFAOYSA-N methyl 2-(2-propan-2-ylanilino)-3h-benzimidazole-5-carboxylate Chemical compound N=1C2=CC(C(=O)OC)=CC=C2NC=1NC1=CC=CC=C1C(C)C ZMHMODKLQDCJIY-UHFFFAOYSA-N 0.000 description 1
• OUDQTZUKSHPSOE-UHFFFAOYSA-N methyl 2-(pyridin-2-ylamino)-3h-benzimidazole-5-carboxylate Chemical compound N=1C2=CC(C(=O)OC)=CC=C2NC=1NC1=CC=CC=N1 OUDQTZUKSHPSOE-UHFFFAOYSA-N 0.000 description 1
• GFBLASIUAJJITP-UHFFFAOYSA-N methyl 3-[[5-(diethylamino)-6-(1h-indazol-6-ylcarbamoyl)-1h-benzimidazol-2-yl]amino]benzoate Chemical compound N=1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(N(CC)CC)=CC=2NC=1NC1=CC=CC(C(=O)OC)=C1 GFBLASIUAJJITP-UHFFFAOYSA-N 0.000 description 1
• NQXFZEJJHPUMMF-UHFFFAOYSA-N methyl 3-isothiocyanatobenzoate Chemical compound COC(=O)C1=CC=CC(N=C=S)=C1 NQXFZEJJHPUMMF-UHFFFAOYSA-N 0.000 description 1
• 229940102396 methyl bromide Drugs 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 150000004702 methyl esters Chemical class 0.000 description 1
• LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
• JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 230000035773 mitosis phase Effects 0.000 description 1
• 230000036456 mitotic arrest Effects 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 230000008600 mitotic progression Effects 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
• YNADRQHQKCKSCL-UHFFFAOYSA-N morpholine-2,4-diyl Chemical group C1C[O+]=CC[N-]1 YNADRQHQKCKSCL-UHFFFAOYSA-N 0.000 description 1
• YNAVUWVOSKDBBP-UHFFFAOYSA-O morpholinium Chemical compound [H+].C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-O 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 230000002071 myeloproliferative effect Effects 0.000 description 1
• HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 1
• AHDVLVISVNHSIO-UHFFFAOYSA-N n-(1,3-benzothiazol-5-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1=C2NC=NC2=CC(C(NC=2C=C3N=CSC3=CC=2)=O)=C1 AHDVLVISVNHSIO-UHFFFAOYSA-N 0.000 description 1
• PMBPMXKHOKCPND-UHFFFAOYSA-N n-(1,3-benzothiazol-6-yl)-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1NC1=NC2=CC(C(=O)NC=3C=C4SC=NC4=CC=3)=CC=C2N1 PMBPMXKHOKCPND-UHFFFAOYSA-N 0.000 description 1
• BHZWELVLEZTCJP-UHFFFAOYSA-N n-(1,3-benzothiazol-6-yl)-2-chloro-4-fluoro-5-nitrobenzamide Chemical compound C1=C(F)C([N+](=O)[O-])=CC(C(=O)NC=2C=C3SC=NC3=CC=2)=C1Cl BHZWELVLEZTCJP-UHFFFAOYSA-N 0.000 description 1
• KNYYOPAKAHDGLD-UHFFFAOYSA-N n-(1,3-benzothiazol-6-yl)-6-(4-methylpiperazin-1-yl)-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound C1CN(C)CCN1C(C(=C1)C(=O)NC=2C=C3SC=NC3=CC=2)=CC2=C1N=C(NC=1C(=CC=CC=1)C(F)(F)F)N2 KNYYOPAKAHDGLD-UHFFFAOYSA-N 0.000 description 1
• HGKKIKFZSFFVNL-UHFFFAOYSA-N n-(1h-indazol-5-yl)-6-(4-methylpiperazin-1-yl)-2-[[1-(thietan-3-yl)imidazol-2-yl]amino]-3h-benzimidazole-5-carboxamide Chemical compound C1CN(C)CCN1C(C(=C1)C(=O)NC=2C=C3C=NNC3=CC=2)=CC2=C1NC(NC=1N(C=CN=1)C1CSC1)=N2 HGKKIKFZSFFVNL-UHFFFAOYSA-N 0.000 description 1
• ISPBDBMDORQLLI-UHFFFAOYSA-N n-(1h-indazol-6-yl)-2-[(1-propan-2-ylimidazol-2-yl)amino]-3h-benzimidazole-5-carboxamide Chemical compound CC(C)N1C=CN=C1NC1=NC2=CC=C(C(=O)NC=3C=C4NN=CC4=CC=3)C=C2N1 ISPBDBMDORQLLI-UHFFFAOYSA-N 0.000 description 1
• QPUOOCDMCMTNPY-UHFFFAOYSA-N n-(1h-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-1,3-benzoxazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1NC1=NC2=CC(C(=O)NC=3C=C4NN=CC4=CC=3)=CC=C2O1 QPUOOCDMCMTNPY-UHFFFAOYSA-N 0.000 description 1
• SQNTWOGOYBWWPR-UHFFFAOYSA-N n-(1h-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-2-(2-propan-2-ylanilino)-3h-benzimidazole-5-carboxamide Chemical compound CC(C)C1=CC=CC=C1NC1=NC2=CC(C(=O)NC=3C=C4NN=CC4=CC=3)=C(N3CCN(C)CC3)C=C2N1 SQNTWOGOYBWWPR-UHFFFAOYSA-N 0.000 description 1
• HTWYHKBLZLPQFU-UHFFFAOYSA-N n-(1h-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-2-sulfanylidene-1,3-dihydrobenzimidazole-5-carboxamide Chemical compound C1CN(C)CCN1C(C(=C1)C(=O)NC=2C=C3NN=CC3=CC=2)=CC2=C1N=C(S)N2 HTWYHKBLZLPQFU-UHFFFAOYSA-N 0.000 description 1
• TUWICOFKUUWVIT-UHFFFAOYSA-N n-(1h-indazol-6-yl)benzamide Chemical compound C=1C=C2C=NNC2=CC=1NC(=O)C1=CC=CC=C1 TUWICOFKUUWVIT-UHFFFAOYSA-N 0.000 description 1
• RUTREIHYSRJFHR-UHFFFAOYSA-N n-(2-morpholin-4-ylethyl)-6-nitro-1h-indazol-3-amine Chemical compound N=1NC2=CC([N+](=O)[O-])=CC=C2C=1NCCN1CCOCC1 RUTREIHYSRJFHR-UHFFFAOYSA-N 0.000 description 1
• OKGNQFHVWQVTQE-UHFFFAOYSA-N n-(3-chloro-2h-indazol-6-yl)-2-(2-ethylanilino)-3h-benzimidazole-5-carboxamide Chemical compound CCC1=CC=CC=C1NC1=NC2=CC=C(C(=O)NC=3C=C4NN=C(Cl)C4=CC=3)C=C2N1 OKGNQFHVWQVTQE-UHFFFAOYSA-N 0.000 description 1
• YRVVRBJYFXFXNT-UHFFFAOYSA-N n-(3-methoxy-1h-indazol-6-yl)-2-(2-propan-2-ylanilino)-3h-benzimidazole-5-carboxamide Chemical compound C=1C=C2C(OC)=NNC2=CC=1NC(=O)C(C=C1N2)=CC=C1N=C2NC1=CC=CC=C1C(C)C YRVVRBJYFXFXNT-UHFFFAOYSA-N 0.000 description 1
• KAAUENQFMSCFLM-UHFFFAOYSA-N n-[1-(2-hydroxyethyl)indazol-5-yl]-2-(2-propan-2-ylanilino)-3h-benzimidazole-5-carboxamide Chemical compound CC(C)C1=CC=CC=C1NC1=NC2=CC=C(C(=O)NC=3C=C4C=NN(CCO)C4=CC=3)C=C2N1 KAAUENQFMSCFLM-UHFFFAOYSA-N 0.000 description 1
• FGWBYJKTBBIOPV-UHFFFAOYSA-N n-[2-(2-propan-2-ylanilino)-3h-benzimidazol-5-yl]-1h-indazole-6-carboxamide Chemical compound CC(C)C1=CC=CC=C1NC(NC1=C2)=NC1=CC=C2NC(=O)C1=CC=C(C=NN2)C2=C1 FGWBYJKTBBIOPV-UHFFFAOYSA-N 0.000 description 1
• RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
• CANLIPVYLYDYOL-UHFFFAOYSA-N n-benzyl-5-(1h-indazol-6-yloxy)-2-nitroaniline Chemical compound [O-][N+](=O)C1=CC=C(OC=2C=C3NN=CC3=CC=2)C=C1NCC1=CC=CC=C1 CANLIPVYLYDYOL-UHFFFAOYSA-N 0.000 description 1
• ZQLZSKZOTVXWNW-UHFFFAOYSA-N n-cyclopentyl-2-nitroaniline Chemical compound [O-][N+](=O)C1=CC=CC=C1NC1CCCC1 ZQLZSKZOTVXWNW-UHFFFAOYSA-N 0.000 description 1
• JZPTXQGCBNSCFY-UHFFFAOYSA-N n-cyclopentyl-6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-amine Chemical compound C1CN(C)CCN1C1=CC=C(N=C(NC2CCCC2)N2)C2=C1 JZPTXQGCBNSCFY-UHFFFAOYSA-N 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000017095 negative regulation of cell growth Effects 0.000 description 1
• 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
• 201000011519 neuroendocrine tumor Diseases 0.000 description 1
• 108010091047 neurofilament protein H Proteins 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 230000009701 normal cell proliferation Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000012038 nucleophile Substances 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 238000005580 one pot reaction Methods 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 229940014662 pantothenate Drugs 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229940046159 pegylated liposomal doxorubicin Drugs 0.000 description 1
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 150000004986 phenylenediamines Chemical class 0.000 description 1
• 150000008105 phosphatidylcholines Chemical class 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 238000003566 phosphorylation assay Methods 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920000570 polyether Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
• 229920000151 polyglycol Polymers 0.000 description 1
• 239000010695 polyglycol Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 150000004804 polysaccharides Chemical class 0.000 description 1
• 229920000136 polysorbate Chemical class 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229940068965 polysorbates Drugs 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
• QPMDWIOUHQWKHV-ODZAUARKSA-M potassium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound [K+].OC(=O)\C=C/C([O-])=O QPMDWIOUHQWKHV-ODZAUARKSA-M 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• 238000011045 prefiltration Methods 0.000 description 1
• 230000005522 programmed cell death Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 239000003909 protein kinase inhibitor Substances 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 150000004040 pyrrolidinones Chemical class 0.000 description 1
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• 239000002287 radioligand Substances 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
• 229960003440 semustine Drugs 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000015424 sodium Nutrition 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 235000010288 sodium nitrite Nutrition 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910001495 sodium tetrafluoroborate Inorganic materials 0.000 description 1
• ABBQHOQBGMUPJH-UHFFFAOYSA-N sodium;2-hydroxybenzoic acid Chemical compound [Na+].OC(=O)C1=CC=CC=C1O ABBQHOQBGMUPJH-UHFFFAOYSA-N 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000009044 synergistic interaction Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229950002757 teoclate Drugs 0.000 description 1
• WZCLRSLCLXOJGD-UHFFFAOYSA-N tert-butyl 2-[[6-(1h-indazol-6-ylcarbamoyl)-1h-benzimidazol-2-yl]amino]-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate Chemical compound C1=C2C=NNC2=CC(NC(=O)C2=CC=C3N=C(NC3=C2)NC2=NC=3CCN(CC=3S2)C(=O)OC(C)(C)C)=C1 WZCLRSLCLXOJGD-UHFFFAOYSA-N 0.000 description 1
• RGWGRRBHQUREDE-UHFFFAOYSA-N tert-butyl 3-bromo-4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)C(Br)C1 RGWGRRBHQUREDE-UHFFFAOYSA-N 0.000 description 1
• UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 1
• XAWJJKQKZJMYMG-UHFFFAOYSA-N tert-butyl 4-[4,5-diamino-2-(1,3-benzothiazol-6-ylcarbamoyl)phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC(N)=C(N)C=C1C(=O)NC1=CC=C(N=CS2)C2=C1 XAWJJKQKZJMYMG-UHFFFAOYSA-N 0.000 description 1
• ZUXHZKBXGYAWDO-UHFFFAOYSA-N tert-butyl 4-[4,5-diamino-2-[(5-methyl-1h-indazol-6-yl)carbamoyl]phenyl]piperazine-1-carboxylate Chemical compound CC1=CC=2C=NNC=2C=C1NC(=O)C1=CC(N)=C(N)C=C1N1CCN(C(=O)OC(C)(C)C)CC1 ZUXHZKBXGYAWDO-UHFFFAOYSA-N 0.000 description 1
• ZOJKIJZQMHGQQU-UHFFFAOYSA-N tert-butyl 4-[5-amino-2-(1,3-benzothiazol-6-ylcarbamoyl)-4-nitrophenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC(N)=C([N+]([O-])=O)C=C1C(=O)NC1=CC=C(N=CS2)C2=C1 ZOJKIJZQMHGQQU-UHFFFAOYSA-N 0.000 description 1
• NQYXLZKDPQOWKC-UHFFFAOYSA-N tert-butyl 4-[6-(1,3-benzothiazol-6-ylcarbamoyl)-2-[2-(trifluoromethyl)anilino]-1h-benzimidazol-5-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(C(=C1)C(=O)NC=2C=C3SC=NC3=CC=2)=CC2=C1N=C(NC=1C(=CC=CC=1)C(F)(F)F)N2 NQYXLZKDPQOWKC-UHFFFAOYSA-N 0.000 description 1
• ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
• AJQCYRQQFCZGNE-UHFFFAOYSA-N tert-butyl n-(2-cyclohexylphenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1C1CCCCC1 AJQCYRQQFCZGNE-UHFFFAOYSA-N 0.000 description 1
• KOYPJRPYUJYATK-UHFFFAOYSA-N tert-butyl n-(3-methylthiophen-2-yl)carbamate Chemical compound CC=1C=CSC=1NC(=O)OC(C)(C)C KOYPJRPYUJYATK-UHFFFAOYSA-N 0.000 description 1
• CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
• 229960003433 thalidomide Drugs 0.000 description 1
• VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 229940035024 thioglycerol Drugs 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
• 229960002622 triacetin Drugs 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• 229940066528 trichloroacetate Drugs 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
• CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 229940070710 valerate Drugs 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1